[S02DA03, antipyrine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Antipyrine.]
[G03XB02, ulipristal, The serum concentration of Ulipristal can be decreased when it is combined with Bosentan.]
[B01AD01, streptokinase, Streptokinase may increase the hypotensive activities of Bosentan.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Bosentan.]
[S01AB01, sulfamethizole, The metabolism of Bosentan can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, Bosentan may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01EC03, sulfamoxole, The metabolism of Bosentan can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Bosentan can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, Bosentan may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Bosentan.]
[M01AB02, sulindac, The therapeutic efficacy of Bosentan can be decreased when used in combination with Sulindac.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Bosentan.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be increased when used in combination with Bosentan.]
[M01AX04, apazone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Azapropazone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Bosentan.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Bosentan.]
[R03CC03, terbutaline, Terbutaline may decrease the antihypertensive activities of Bosentan.]
[G03BA03, testosterone, The metabolism of Testosterone can be increased when combined with Bosentan.]
[N05AE05, lurasidone, Lurasidone may decrease the antihypertensive activities of Bosentan.]
[A04AD10, dronabinol, The metabolism of Dronabinol can be increased when combined with Bosentan.]
[N04BC07, apomorphine, Apomorphine may increase the hypotensive activities of Bosentan.]
[L04AX02, thalidomide, The metabolism of Thalidomide can be increased when combined with Bosentan.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Bosentan.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Bosentan.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Bosentan.]
[N05AB08, thioproperazine, Thioproperazine may decrease the antihypertensive activities of Bosentan.]
[N05AC02, thioridazine, Thioridazine may decrease the antihypertensive activities of Bosentan.]
[G04BE06, moxisylyte, Moxisylyte may decrease the antihypertensive activities of Bosentan.]
[B01AC05, ticlopidine, The metabolism of Bosentan can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, Timolol may increase the hypotensive activities of Bosentan.]
[P01AB02, tinidazole, Bosentan may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Bosentan.]
[M02AX02, tolazoline, Tolazoline may decrease the antihypertensive activities of Bosentan.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Bosentan.]
[M02AA21, tolmetin, The therapeutic efficacy of Bosentan can be decreased when used in combination with Tolmetin.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Bosentan.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypotensive activities of Bosentan.]
[N06AX05, trazodone, Trazodone may decrease the antihypertensive activities of Bosentan.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be increased when combined with Bosentan.]
[C03DB02, triamterene, Triamterene may increase the hypotensive activities of Bosentan.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Trichlormethiazide.]
[N05AB06, trifluoperazine, Trifluoperazine may decrease the antihypertensive activities of Bosentan.]
[S01ED04, metipranolol, Bosentan may increase the hypotensive activities of Metipranolol.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be increased when combined with Bosentan.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Bosentan is combined with Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be increased when combined with Bosentan.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be increased when combined with Bosentan.]
[J01FA08, troleandomycin, The metabolism of Bosentan can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, Vilazodone may decrease the antihypertensive activities of Bosentan.]
[C09CA09, azilsartan medoxomil, Bosentan may increase the hypotensive activities of Azilsartan medoxomil.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be increased when combined with Bosentan.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Bosentan.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be increased when combined with Bosentan.]
[J05AP03, boceprevir, The metabolism of Bosentan can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Bosentan can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Bosentan.]
[R03AC18, indacaterol, Indacaterol may decrease the antihypertensive activities of Bosentan.]
[B01AC24, ticagrelor, The metabolism of Bosentan can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Bosentan can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Bosentan can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Bosentan.]
[C04AX07, vincamine, Bosentan may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Bosentan.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Bosentan.]
[B01AA03, warfarin, The metabolism of Warfarin can be increased when combined with Bosentan.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Bosentan.]
[C03BA10, xipamide, Bosentan may increase the hypotensive activities of Xipamide.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be increased when combined with Bosentan.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be increased when combined with Bosentan.]
[J05AE02, indinavir, The serum concentration of Bosentan can be increased when it is combined with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Bosentan.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Bosentan.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Bosentan.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be increased when combined with Bosentan.]
[N05AE04, ziprasidone, Ziprasidone may increase the antihypertensive activities of Bosentan.]
[G03AC10, drospirenone, The serum concentration of Drospirenone can be decreased when it is combined with Bosentan.]
[N02BA01, aspirin, The metabolism of Acetylsalicylic acid can be increased when combined with Bosentan.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Bosentan.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be increased when combined with Bosentan.]
[C07AB03, atenolol, Bosentan may decrease the excretion rate of Atenolol which could result in a higher serum level.]
[L01FA01, rituximab, Bosentan may increase the hypotensive activities of Rituximab.]
[J02AC03, voriconazole, The metabolism of Bosentan can be decreased when combined with Voriconazole.]
[S01FA01, atropine, Bosentan may decrease the excretion rate of Atropine which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be increased when combined with Bosentan.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Bosentan.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Bosentan.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Bosentan.]
[G04BD12, mirabegron, Mirabegron may decrease the antihypertensive activities of Bosentan.]
[V03AX03, cobicistat, The serum concentration of Bosentan can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Bosentan can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Bosentan can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Bosentan.]
[L04AA31, teriflunomide, The excretion of Bosentan can be decreased when combined with Teriflunomide.]
[C01CA18, octopamine, Octopamine may decrease the antihypertensive activities of Bosentan.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Bosentan.]
[J05AE04, nelfinavir, The serum concentration of Bosentan can be increased when it is combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Bosentan.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Bosentan.]
[C08CA13, lercanidipine, Lercanidipine may increase the hypotensive activities of Bosentan.]
[N06DA02, donepezil, The metabolism of Donepezil can be increased when combined with Bosentan.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Bosentan.]
[N02CC03, zolmitriptan, Zolmitriptan may decrease the antihypertensive activities of Bosentan.]
[N01AA01, ethyl ether, Diethyl ether may decrease the antihypertensive activities of Bosentan.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be increased when combined with Bosentan.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be increased when combined with Bosentan.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Bosentan.]
[B01AF02, apixaban, The metabolism of Apixaban can be increased when combined with Bosentan.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Bosentan.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Bosentan.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Bosentan.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be increased when combined with Bosentan.]
[N02BA10, benorilate, The therapeutic efficacy of Bosentan can be decreased when used in combination with Benorilate.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bosentan.]
[M04AB03, benzbromarone, Bosentan may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin detemir.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be increased when used in combination with Bosentan.]
[J02AX04, caspofungin, The excretion of Bosentan can be decreased when combined with Caspofungin.]
[M01AH01, celecoxib, The therapeutic efficacy of Bosentan can be decreased when used in combination with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may decrease the antihypertensive activities of Bosentan.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Bosentan resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Bosentan.]
[L01EC02, dabrafenib, The serum concentration of Bosentan can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Benzydamine.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Bosentan.]
[C08EA02, bepridil, Bosentan may increase the hypotensive activities of Bepridil.]
[C02KX05, riociguat, Bosentan may increase the hypotensive activities of Riociguat.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be increased when used in combination with Bosentan.]
[A05AA03, cholic acid, Bosentan may decrease the excretion rate of Cholic Acid which could result in a higher serum level.]
[C02KX04, macitentan, Bosentan may increase the hypotensive activities of Macitentan.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be increased when combined with Bosentan.]
[G03AC08, etonogestrel, The serum concentration of Etonogestrel can be decreased when it is combined with Bosentan.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Bosentan.]
[N03AG01, valproic acid, The metabolism of Bosentan can be decreased when combined with Valproic acid.]
[A05AA02, ursodiol, Bosentan may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Bosentan can be decreased when combined with Fusidic acid.]
[J05AP05, simeprevir, The metabolism of Bosentan can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Bosentan.]
[C01CA27, droxidopa, Droxidopa may decrease the antihypertensive activities of Bosentan.]
[C07AB04, acebutolol, Bosentan may increase the hypotensive activities of Acebutolol.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be increased when combined with Bosentan.]
[A16AA07, metreleptin, The metabolism of Bosentan can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Bosentan can be increased when combined with Apremilast.]
[S01ED02, betaxolol, Betaxolol may increase the hypotensive activities of Bosentan.]
[C02CC01, bethanidine, Bethanidine may decrease the antihypertensive activities of Bosentan.]
[C10AB02, bezafibrate, The excretion of Bosentan can be decreased when combined with Bezafibrate.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be increased when used in combination with Bosentan.]
[L04AC11, siltuximab, The metabolism of Bosentan can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be increased when combined with Bosentan.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be increased when combined with Bosentan.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be increased when combined with Bosentan.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Bosentan.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bosentan.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be increased when combined with Bosentan.]
[S01EE02, unoprostone, Bosentan may increase the hypotensive activities of Unoprostone.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be increased when combined with Bosentan.]
[J01XA05, oritavancin, The metabolism of Bosentan can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, Acepromazine may decrease the antihypertensive activities of Bosentan.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be increased when used in combination with Bosentan.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be increased when combined with Bosentan.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Bosentan.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Bosentan.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be increased when combined with Bosentan.]
[N06AX11, mirtazapine, Mirtazapine may decrease the antihypertensive activities of Bosentan.]
[L04AC10, secukinumab, The metabolism of Bosentan can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Bosentan.]
[L01EX08, lenvatinib, The risk or severity of liver damage can be increased when Bosentan is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Bosentan.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be increased when combined with Bosentan.]
[J05AP06, asunaprevir, The serum concentration of Bosentan can be increased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, The excretion of Bosentan can be decreased when combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may decrease the antihypertensive activities of Bosentan.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Bosentan.]
[A04AD14, rolapitant, The metabolism of Rolapitant can be increased when combined with Bosentan.]
[G02CX02, flibanserin, Flibanserin may decrease the antihypertensive activities of Bosentan.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be increased when combined with Bosentan.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be increased when used in combination with Bosentan.]
[M02AA25, aceclofenac, The therapeutic efficacy of Bosentan can be decreased when used in combination with Aceclofenac.]
[M01AB11, acemetacin, The therapeutic efficacy of Bosentan can be decreased when used in combination with Acemetacin.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin degludec.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be increased when combined with Bosentan.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Bosentan.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be increased when combined with Bosentan.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Bosentan.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be increased when combined with Bosentan.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Bosentan.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Bosentan.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Bosentan.]
[B01AC27, selexipag, Bosentan may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Bosentan.]
[G04CA01, alfuzosin, Alfuzosin may increase the hypotensive activities of Bosentan.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be increased when combined with Bosentan.]
[M01AE16, alminoprofen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Alminoprofen.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be increased when combined with Bosentan.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Bosentan.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Bosentan.]
[N06AA19, amineptin, Amineptine may decrease the antihypertensive activities of Bosentan.]
[C08CA01, amlodipine, Amlodipine may increase the hypotensive activities of Bosentan.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Bosentan.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Bosentan is combined with Obeticholic acid.]
[C03CA02, bumetanide, Bumetanide may increase the hypotensive activities of Bosentan.]
[N01BB01, bupivacaine, Bupivacaine may increase the hypotensive activities of Bosentan.]
[C07AA19, bupranolol, Bosentan may increase the hypotensive activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be increased when combined with Bosentan.]
[N05BE01, buspirone, Buspirone may decrease the antihypertensive activities of Bosentan.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Bosentan.]
[L01XX27, arsenic trioxide, Arsenic trioxide may increase the hypotensive activities of Bosentan.]
[P01BE02, artemether, The metabolism of Artemether can be increased when combined with Bosentan.]
[S01GX07, azelastine, The metabolism of Azelastine can be increased when combined with Bosentan.]
[L01XK03, rucaparib, The metabolism of Bosentan can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be increased when combined with Bosentan.]
[L01EF02, ribociclib, The metabolism of Bosentan can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The therapeutic efficacy of Bosentan can be decreased when used in combination with Balsalazide.]
[R03CC12, bambuterol, Bambuterol may decrease the antihypertensive activities of Bosentan.]
[C09AA07, benazepril, Benazepril may increase the hypotensive activities of Bosentan.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be increased when used in combination with Bosentan.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Bosentan.]
[J05AE09, tipranavir, The serum concentration of Bosentan can be increased when it is combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Bosentan can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Bosentan can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Bosentan.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Bosentan.]
[J01MA23, delafloxacin, The metabolism of Bosentan can be increased when combined with Delafloxacin.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be increased when combined with Bosentan.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Bosentan.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Bosentan.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Bosentan.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Bosentan.]
[C07AB07, bisoprolol, Bosentan may increase the hypotensive activities of Bisoprolol.]
[R03AC17, bitolterol, Bitolterol may decrease the antihypertensive activities of Bosentan.]
[J05AG03, efavirenz, The metabolism of Bosentan can be decreased when combined with Efavirenz.]
[C01DX19, nesiritide, Nesiritide may increase the hypotensive activities of Bosentan.]
[V03AB23, acetylcysteine, The excretion of Bosentan can be decreased when combined with Acetylcysteine.]
[R03BA02, budesonide, Bosentan may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Bosentan.]
[M01AB07, bumadizone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Bosentan.]
[J05AX18, letermovir, The risk or severity of liver damage can be increased when Bosentan is combined with Letermovir.]
[N06AA15, butriptyline, Butriptyline may decrease the antihypertensive activities of Bosentan.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be increased when used in combination with Bosentan.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Bosentan.]
[C09AA01, captopril, Bosentan may increase the hypotensive activities of Captopril.]
[L02BB05, apalutamide, The metabolism of Bosentan can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be increased when combined with Bosentan.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be increased when combined with Bosentan.]
[B02BX09, fostamatinib, Fostamatinib may increase the antihypertensive activities of Bosentan.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be increased when combined with Bosentan.]
[B02BX08, avatrombopag, The metabolism of Bosentan can be increased when combined with Avatrombopag.]
[C07AB08, celiprolol, Bosentan may increase the hypotensive activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Bosentan can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Bosentan can be decreased when combined with Stiripentol.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Bosentan.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Bosentan.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Bosentan.]
[N01BA04, chloroprocaine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Chloroprocaine.]
[M01AC05, lornoxicam, The therapeutic efficacy of Bosentan can be decreased when used in combination with Lornoxicam.]
[L04AA39, emapalumab, The metabolism of Bosentan can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Bosentan.]
[C09AA08, cilazapril, Bosentan may increase the hypotensive activities of Cilazapril.]
[A03FA08, cinitapride, Cinitapride may decrease the antihypertensive activities of Bosentan.]
[S01ED05, carteolol, Carteolol may increase the hypotensive activities of Bosentan.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be increased when combined with Bosentan.]
[N06AX27, esketamine, The metabolism of Esketamine can be increased when combined with Bosentan.]
[L04AA42, siponimod, The therapeutic efficacy of Siponimod can be decreased when used in combination with Bosentan.]
[J01FA09, clarithromycin, The serum concentration of 14-OH-Clarithromycin, an active metabolite of Bosentan, can be increased when used in combination with Clarithromycin.]
[N06BA14, solriamfetol, Solriamfetol may decrease the antihypertensive activities of Bosentan.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Bosentan.]
[C09CA06, candesartan, The metabolism of Candesartan can be increased when combined with Bosentan.]
[L04AB01, etanercept, The metabolism of Bosentan can be increased when combined with Etanercept.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Bosentan resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EM03, alpelisib, The serum concentration of Bosentan can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, Bosentan may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be decreased when it is combined with Bosentan.]
[L01EX15, pexidartinib, Bosentan may increase the hepatotoxic activities of Pexidartinib.]
[C03BX03, cicletanine, Bosentan may increase the hypotensive activities of Cicletanine.]
[L01EJ02, fedratinib, The excretion of Bosentan can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Bosentan.]
[N07XX11, pitolisant, The serum concentration of Bosentan can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Bosentan.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Bosentan.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be increased when combined with Bosentan.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may decrease the antihypertensive activities of Bosentan.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin pork.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Bosentan.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be decreased when it is combined with Bosentan.]
[G03DB05, demegestone, The serum concentration of Demegestone can be decreased when it is combined with Bosentan.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Bosentan.]
[G03AC09, desogestrel, The serum concentration of Desogestrel can be decreased when it is combined with Bosentan.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be decreased when it is combined with Bosentan.]
[N03AX25, cenobamate, The serum concentration of Bosentan can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be decreased when it is combined with Bosentan.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be increased when combined with Bosentan.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Bosentan.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Bosentan.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Bosentan.]
[M01AX21, diacetylrhein, The metabolism of Bosentan can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Bosentan.]
[C10AX15, bempedoic acid, The excretion of Bosentan can be decreased when combined with Bempedoic acid.]
[J05AE05, amprenavir, The serum concentration of Bosentan can be increased when it is combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may decrease the antihypertensive activities of Bosentan.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Bosentan.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be decreased when it is combined with Bosentan.]
[G03DB08, dienogest, The serum concentration of Dienogest can be decreased when it is combined with Bosentan.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be increased when combined with Bosentan.]
[M01AH02, rofecoxib, The therapeutic efficacy of Bosentan can be decreased when used in combination with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Bexarotene can be increased when combined with Bosentan.]
[C08CA16, clevidipine, The metabolism of Bosentan can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Bosentan.]
[C02AA06, methoserpidine, Bosentan may increase the hypotensive activities of Methoserpidine.]
[L01EN02, pemigatinib, The metabolism of Pemigatinib can be increased when combined with Bosentan.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Bosentan.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Bosentan.]
[N04BX04, opicapone, Opicapone may increase the hypotensive activities of Bosentan.]
[C01CA14, dopexamine, Dopexamine may decrease the antihypertensive activities of Bosentan.]
[M01AC04, droxicam, The therapeutic efficacy of Bosentan can be decreased when used in combination with Droxicam.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Bosentan.]
[M02AA27, dexketoprofen, The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bosentan.]
[L01XX69, lurbinectedin, The serum concentration of Lurbinectedin can be decreased when it is combined with Bosentan.]
[C08CA17, levamlodipine, Bosentan may increase the hypotensive activities of Levamlodipine.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Bosentan.]
[J05AX29, fostemsavir, The excretion of Bosentan can be decreased when combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Proguanil can be increased when combined with Bosentan.]
[L01FX15, belantamab mafodotin, Bosentan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The serum concentration of Bosentan can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be decreased when it is combined with Bosentan.]
[L01EX23, pralsetinib, The risk or severity of liver damage can be increased when Bosentan is combined with Pralsetinib.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Chlorothiazide.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be increased when combined with Bosentan.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Bosentan.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the hypotensive activities of Bosentan.]
[V04CK02, cholecystokinin, The excretion of Bosentan can be decreased when combined with Cholecystokinin.]
[N02BA07, ethenzamide, The therapeutic efficacy of Bosentan can be decreased when used in combination with Ethenzamide.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Bosentan resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03DC06, ethynodiol, The serum concentration of Etynodiol can be decreased when it is combined with Bosentan.]
[M01AB08, etodolac, The therapeutic efficacy of Bosentan can be decreased when used in combination with Etodolac.]
[M02AA06, etofenamate, The therapeutic efficacy of Bosentan can be decreased when used in combination with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Bosentan can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Bosentan can be decreased when combined with Lonafarnib.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Bosentan.]
[L04AD03, voclosporin, The metabolism of Voclosporin can be increased when combined with Bosentan.]
[P03AX07, abametapir, The serum concentration of Bosentan can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, Vericiguat may increase the hypotensive activities of Bosentan.]
[L01EX21, tepotinib, The metabolism of Bosentan can be decreased when combined with Tepotinib.]
[N03AX10, felbamate, The metabolism of Bosentan can be decreased when combined with Felbamate.]
[M01AE05, fenbufen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Fenbufen.]
[C01CA19, fenoldopam, Bosentan may increase the hypotensive activities of Fenoldopam.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Bosentan.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Bosentan.]
[S01JA01, fluorescein, Bosentan may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be increased when combined with Bosentan.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin human.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Bosentan.]
[N01AB05, trichloroethylene, Trichloroethylene may decrease the antihypertensive activities of Bosentan.]
[L03AB10, peginterferon alfa-2b, The metabolism of Bosentan can be increased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Bosentan may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The risk or severity of liver damage can be increased when Cimetidine is combined with Bosentan.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be increased when combined with Bosentan.]
[L01XX73, sotorasib, The serum concentration of Bosentan can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Bosentan.]
[S03AA07, ciprofloxacin, The metabolism of Bosentan can be decreased when combined with Ciprofloxacin.]
[J02AX07, ibrexafungerp, The serum concentration of Ibrexafungerp can be decreased when it is combined with Bosentan.]
[C03DA05, finerenone, The therapeutic efficacy of Finerenone can be decreased when used in combination with Bosentan.]
[L04AA48, belumosudil, The excretion of Bosentan can be decreased when combined with Belumosudil.]
[N02CD07, atogepant, The serum concentration of Atogepant can be decreased when it is combined with Bosentan.]
[M01AG01, mefenamic acid, The therapeutic efficacy of Bosentan can be decreased when used in combination with Mefenamic acid.]
[A10BB12, glimepiride, Bosentan may decrease the excretion rate of Glimepiride which could result in a higher serum level.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Bosentan.]
[R03CC13, clenbuterol, Clenbuterol may decrease the antihypertensive activities of Bosentan.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Bosentan.]
[N06AX25, St. John's wort extract, The metabolism of Bosentan can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Bosentan can be decreased when combined with Asciminib.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be increased when combined with Bosentan.]
[B06AX04, mitapivat, The metabolism of Mitapivat can be increased when combined with Bosentan.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the hypotensive activities of Bosentan.]
[L01EJ03, pacritinib, The serum concentration of Pacritinib can be decreased when it is combined with Bosentan.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Bosentan.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Bosentan.]
[S01EA04, clonidine, The risk or severity of hypotension can be increased when Clonidine is combined with Bosentan.]
[C01EB24, mavacamten, The serum concentration of Bosentan can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be increased when used in combination with Bosentan.]
[N03AX27, ganaxolone, The metabolism of Ganaxolone can be increased when combined with Bosentan.]
[A05BA08, glycyrrhizic acid, Bosentan may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be increased when combined with Bosentan.]
[J05AX31, lenacapavir, The metabolism of Lenacapavir can be increased when combined with Bosentan.]
[N05AH02, clozapine, The metabolism of Bosentan can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be increased when used in combination with Bosentan.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Bosentan.]
[H01AC08, somatrogon, The metabolism of Bosentan can be increased when combined with Somatrogon.]
[C02KB01, metyrosine, Bosentan may increase the hypotensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Bosentan can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Proquazone.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Bosentan resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be increased when combined with Bosentan.]
[N01AB07, desflurane, Desflurane may decrease the antihypertensive activities of Bosentan.]
[C04AX28, ifenprodil, Ifenprodil may decrease the antihypertensive activities of Bosentan.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be increased when used in combination with Bosentan.]
[N02BA16, imidazole-2-hydroxybenzoate, The therapeutic efficacy of Bosentan can be decreased when used in combination with Imidazole salicylate.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be increased when used in combination with Bosentan.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Bosentan can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Indobufen.]
[M01AH03, valdecoxib, The therapeutic efficacy of Bosentan can be decreased when used in combination with Valdecoxib.]
[A03AX10, isometheptene, Isometheptene may decrease the antihypertensive activities of Bosentan.]
[N02CC05, almotriptan, Almotriptan may decrease the antihypertensive activities of Bosentan.]
[M01AH04, parecoxib, The therapeutic efficacy of Bosentan can be decreased when used in combination with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Bosentan can be decreased when combined with Itraconazole.]
[M01AA06, kebuzone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Kebuzone.]
[L01EA01, imatinib, Bosentan may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[J02AC04, posaconazole, The metabolism of Bosentan can be decreased when combined with Posaconazole.]
[S01EE04, travoprost, Travoprost may increase the hypotensive activities of Bosentan.]
[S01EE03, bimatoprost, Bosentan may increase the hypotensive activities of Bimatoprost.]
[C08CA09, lacidipine, Bosentan may increase the hypotensive activities of Lacidipine.]
[N07BC04, lofexidine, Lofexidine may decrease the antihypertensive activities of Bosentan.]
[M01AB09, lonazolac, The therapeutic efficacy of Bosentan can be decreased when used in combination with Lonazolac.]
[R06AX13, loratadine, Bosentan may decrease the excretion rate of Loratadine which could result in a higher serum level.]
[M02AA31, loxoprofen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Loxoprofen.]
[C09AA03, lisinopril, Bosentan may increase the hypotensive activities of Lisinopril.]
[C08CA11, manidipine, The metabolism of Bosentan can be decreased when combined with Manidipine.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Bosentan.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the antihypertensive activities of Bosentan.]
[R06AE03, cyclizine, The metabolism of Bosentan can be decreased when combined with Cyclizine.]
[C03DA04, eplerenone, Bosentan may increase the hypotensive activities of Eplerenone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be increased when used in combination with Bosentan.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Bosentan.]
[N06AX07, minaprine, Minaprine may increase the hypotensive activities of Bosentan.]
[S01XA18, cyclosporine, The serum concentration of Bosentan can be increased when it is combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Bosentan.]
[N06BA07, modafinil, The metabolism of Bosentan can be decreased when combined with Armodafinil.]
[C09AA13, moexipril, Bosentan may increase the hypotensive activities of Moexipril.]
[C10AA07, rosuvastatin, The serum concentration of Rosuvastatin can be decreased when it is combined with Bosentan.]
[M02AA02, mofebutazone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Mofebutazone.]
[M01AX22, morniflumate, The therapeutic efficacy of Bosentan can be decreased when used in combination with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Bosentan can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Moxonidine may decrease the antihypertensive activities of Bosentan.]
[G04BE09, vardenafil, Vardenafil may increase the antihypertensive activities of Bosentan.]
[M01AH05, etoricoxib, The therapeutic efficacy of Bosentan can be decreased when used in combination with Etoricoxib.]
[G03XA01, danazol, The metabolism of Bosentan can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dapsone can be increased when combined with Bosentan.]
[L01DB02, daunorubicin, Bosentan may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C02CC04, debrisoquin, Bosentan may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The metabolism of Nabilone can be increased when combined with Bosentan.]
[M01AX01, nabumetone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Nabumetone.]
[C07AB12, nebivolol, Bosentan may increase the hypotensive activities of Nebivolol.]
[N06AX06, nefazodone, The metabolism of Bosentan can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Bosentan may increase the hypotensive activities of Nicorandil.]
[L02BB02, nilutamide, The metabolism of Bosentan can be decreased when combined with Nilutamide.]
[G03DB04, nomegestrol, The serum concentration of Nomegestrol can be decreased when it is combined with Bosentan.]
[C01CA23, theodrenaline, Theodrenaline may decrease the antihypertensive activities of Bosentan.]
[C01CA05, norfenefrine, Norfenefrine may decrease the antihypertensive activities of Bosentan.]
[G04BD08, solifenacin, Solifenacin may decrease the antihypertensive activities of Bosentan.]
[A07EC03, olsalazine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Olsalazine.]
[N06AA01, desipramine, Desipramine may decrease the antihypertensive activities of Bosentan.]
[H01BA02, desmopressin, Desmopressin may decrease the antihypertensive activities of Bosentan.]
[C09XA02, aliskiren, Bosentan may increase the hypotensive activities of Aliskiren.]
[M01AE12, oxaprozin, The therapeutic efficacy of Bosentan can be decreased when used in combination with Oxaprozin.]
[S03BA01, dexamethasone, The metabolism of Bosentan can be increased when combined with Dexamethasone.]
[L04AB04, adalimumab, The metabolism of Bosentan can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the antihypertensive activities of Bosentan.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be increased when combined with Bosentan.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be increased when combined with Bosentan.]
[N06AB05, paroxetine, The metabolism of Bosentan can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be increased when combined with Bosentan.]
[N05BA01, diazepam, The metabolism of Diazepam can be increased when combined with Bosentan.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Bosentan.]
[N06AA08, dibenzepin, Dibenzepin may decrease the antihypertensive activities of Bosentan.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the hypotensive activities of Bosentan.]
[S01BC03, diclofenac, Bosentan may decrease the excretion rate of Diclofenac which could result in a higher serum level.]
[C02DG01, pinacidil, Bosentan may increase the hypotensive activities of Pinacidil.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Bosentan.]
[N05AD05, pipamperone, Pipamperone may increase the hypotensive activities of Bosentan.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Bosentan.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Bosentan.]
[R03CC07, pirbuterol, Pirbuterol may decrease the antihypertensive activities of Bosentan.]
[A08AA03, diethylpropion, Diethylpropion may decrease the antihypertensive activities of Bosentan.]
[L02AA01, diethylstilbestrol, The serum concentration of Diethylstilbestrol can be decreased when it is combined with Bosentan.]
[C08CA03, isradipine, Bosentan may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[N02BA11, diflunisal, The therapeutic efficacy of Bosentan can be decreased when used in combination with Diflunisal.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be increased when combined with Bosentan.]
[C01AA05, digoxin, Bosentan may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Bosentan may increase the hypotensive activities of Dihydralazine.]
[C10AX09, ezetimibe, Bosentan may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Bosentan may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Bosentan.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be increased when combined with Bosentan.]
[J05AE08, atazanavir, The serum concentration of Atazanavir can be decreased when it is combined with Bosentan.]
[B01AC21, treprostinil, Treprostinil may increase the hypotensive activities of Bosentan.]
[C08DB01, diltiazem, The metabolism of Bosentan can be decreased when combined with Diltiazem.]
[R03CC08, procaterol, Procaterol may decrease the antihypertensive activities of Bosentan.]
[N02BB04, propyphenazone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Propyphenazone.]
[M01AB14, proglumetacin, The therapeutic efficacy of Bosentan can be decreased when used in combination with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Bosentan can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be increased when combined with Bosentan.]
[N05CD10, quazepam, The metabolism of Quazepam can be increased when combined with Bosentan.]
[C09AA06, quinapril, Bosentan may increase the hypotensive activities of Quinapril.]
[B01AC07, dipyridamole, Bosentan may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Bosentan.]
[N06AA23, quinupramine, Quinupramine may decrease the antihypertensive activities of Bosentan.]
[A03FA02, cisapride, The metabolism of Cisapride can be increased when combined with Bosentan.]
[C09AA05, ramipril, Ramipril may increase the hypotensive activities of Bosentan.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Bosentan.]
[R03CC14, reproterol, Reproterol may decrease the antihypertensive activities of Bosentan.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be increased when used in combination with Bosentan.]
[P03AA04, disulfiram, Bosentan may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[S02AA12, rifamycin SV, The metabolism of Bosentan can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Bosentan can be increased when combined with Rifapentine.]
[N05AX08, risperidone, Risperidone may decrease the antihypertensive activities of Bosentan.]
[N01BB09, ropivacaine, Ropivacaine may increase the hypotensive activities of Bosentan.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Bosentan.]
[A04AD12, aprepitant, The metabolism of Bosentan can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Bosentan.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Bosentan.]
[J05AE07, fosamprenavir, The serum concentration of Bosentan can be increased when it is combined with Fosamprenavir.]
[G04BE08, tadalafil, Bosentan may increase the hypotensive activities of Tadalafil.]
[S01BC05, ketorolac, The therapeutic efficacy of Bosentan can be decreased when used in combination with Ketorolac.]
[C02KX02, ambrisentan, Bosentan may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Bosentan.]
[N02BA06, salsalate, The therapeutic efficacy of Bosentan can be decreased when used in combination with Salsalate.]
[R03AC12, salmeterol, Salmeterol may decrease the antihypertensive activities of Bosentan.]
[C01CA07, dobutamine, Dobutamine may decrease the antihypertensive activities of Bosentan.]
[C01CA04, dopamine, Dopamine may decrease the antihypertensive activities of Bosentan.]
[N06AA16, dothiepin, Dosulepin may decrease the antihypertensive activities of Bosentan.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Bosentan.]
[N06AA12, doxepin, The metabolism of Doxepin can be increased when combined with Bosentan.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Bosentan.]
[N06AB06, sertraline, The metabolism of Sertraline can be increased when combined with Bosentan.]
[N01AB08, sevoflurane, Sevoflurane may decrease the antihypertensive activities of Bosentan.]
[N05AD08, droperidol, Droperidol may decrease the antihypertensive activities of Bosentan.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be decreased when it is combined with Bosentan.]
[C09AA11, spirapril, Bosentan may increase the hypotensive activities of Spirapril.]
[N02CC01, sumatriptan, Sumatriptan may decrease the antihypertensive activities of Bosentan.]
[C07AB13, talinolol, Bosentan may increase the hypotensive activities of Talinolol.]
[M01AC02, tenoxicam, The therapeutic efficacy of Bosentan can be decreased when used in combination with Tenoxicam.]
[G04CA03, terazosin, Bosentan may increase the hypotensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be increased when combined with Bosentan.]
[S01GA02, tetrahydrozoline, Tetryzoline may decrease the antihypertensive activities of Bosentan.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Bosentan.]
[C09AA02, enalapril, Bosentan may increase the hypotensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The therapeutic efficacy of Bosentan can be decreased when used in combination with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Bosentan.]
[N06BA09, atomoxetine, Atomoxetine may decrease the antihypertensive activities of Bosentan.]
[C03CA04, torsemide, The metabolism of Torasemide can be increased when combined with Bosentan.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Bosentan.]
[C09AA10, trandolapril, Trandolapril may increase the hypotensive activities of Bosentan.]
[R03CC11, tulobuterol, Tulobuterol may decrease the antihypertensive activities of Bosentan.]
[C02CA06, urapidil, Urapidil may decrease the antihypertensive activities of Bosentan.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Bosentan.]
[S01FB02, ephedrine, Ephedrine may decrease the antihypertensive activities of Bosentan.]
[C01CX07, xamoterol, Xamoterol may decrease the antihypertensive activities of Bosentan.]
[S01GA03, xylometazoline, Xylometazoline may decrease the antihypertensive activities of Bosentan.]
[C08CA12, mepirodipine, Bosentan may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, The metabolism of Bosentan can be decreased when combined with Epinephrine.]
[C09AA15, zofenopril, Bosentan may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Bosentan.]
[M01AB04, zomepirac, The therapeutic efficacy of Bosentan can be decreased when used in combination with Zomepirac.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be increased when combined with Bosentan.]
[C02AC02, guanfacine, Guanfacine may decrease the antihypertensive activities of Bosentan.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Bosentan.]
[G02AB03, ergonovine, Ergometrine may decrease the antihypertensive activities of Bosentan.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may decrease the antihypertensive activities of Bosentan.]
[N02CA02, ergotamine, The metabolism of Bosentan can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, Bosentan may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[A02BC02, pantoprazole, The excretion of Bosentan can be decreased when combined with Pantoprazole.]
[G03CA03, estradiol, The serum concentration of Estradiol can be decreased when it is combined with Bosentan.]
[G03CA57, estrogens, conjugated (USP), The excretion of Bosentan can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Bosentan can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The excretion of Bosentan can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The excretion of Bosentan can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The serum concentration of Fluvastatin can be decreased when it is combined with Bosentan.]
[C01CA15, gepefrine, Gepefrine may decrease the antihypertensive activities of Bosentan.]
[L02AA03, ethinyl estradiol, The serum concentration of Ethinylestradiol can be decreased when it is combined with Bosentan.]
[V03AF05, amifostine, Bosentan may increase the hypotensive activities of Amifostine.]
[M01AC06, meloxicam, The therapeutic efficacy of Bosentan can be decreased when used in combination with Meloxicam.]
[C01CA01, etilefrine, Etilefrine may decrease the antihypertensive activities of Bosentan.]
[N01AX07, etomidate, Etomidate may decrease the antihypertensive activities of Bosentan.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Bosentan.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be increased when combined with Bosentan.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Bosentan.]
[R06AX12, terfenadine, The metabolism of Bosentan can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Bupropion can be increased when combined with Bosentan.]
[N06AB08, fluvoxamine, Bosentan may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be decreased when it is combined with Bosentan.]
[A16AA01, levocarnitine, The excretion of Bosentan can be decreased when combined with Levocarnitine.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Bosentan.]
[C08CA02, felodipine, Bosentan may decrease the excretion rate of Felodipine which could result in a higher serum level.]
[M01AE04, fenoprofen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Fenoprofen.]
[R03CC04, fenoterol, Fenoterol may decrease the antihypertensive activities of Bosentan.]
[N02AB03, fentanyl, Fentanyl may decrease the antihypertensive activities of Bosentan.]
[R03CC02, albuterol, Salbutamol may decrease the antihypertensive activities of Bosentan.]
[L01BB06, clofarabine, Clofarabine may increase the hypotensive activities of Bosentan.]
[C01BC04, flecainide, The metabolism of Bosentan can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Floctafenine.]
[J01CF05, floxacillin, Bosentan may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.]
[J02AC01, fluconazole, The metabolism of Bosentan can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be increased when combined with Bosentan.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be increased when combined with Bosentan.]
[N06AA14, melitracen, Melitracen may decrease the antihypertensive activities of Bosentan.]
[V03AZ01, ethanol, The metabolism of Bosentan can be decreased when combined with Ethanol.]
[L01BC09, floxuridine, The metabolism of Bosentan can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Bosentan can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The metabolism of Bosentan can be decreased when combined with Fluoxetine.]
[N05AF01, flupenthixol, Flupentixol may decrease the antihypertensive activities of Bosentan.]
[S01BC04, flurbiprofen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Flurbiprofen.]
[N06BX17, adrafinil, Adrafinil may decrease the antihypertensive activities of Bosentan.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Bosentan.]
[J05AE10, darunavir, The serum concentration of Darunavir can be decreased when it is combined with Bosentan.]
[C03CA01, furosemide, Bosentan may increase the hypotensive activities of Furosemide.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be decreased when it is combined with Bosentan.]
[C10AB04, gemfibrozil, The metabolism of Bosentan can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Bosentan.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Bosentan.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be increased when used in combination with Bosentan.]
[J05AG04, etravirine, The metabolism of Etravirine can be increased when combined with Bosentan.]
[G03XA02, gestrinone, The serum concentration of Gestrinone can be decreased when it is combined with Bosentan.]
[N01AH02, alfentanil, Alfentanil may decrease the antihypertensive activities of Bosentan.]
[A10BB01, glyburide, Glyburide may increase the hepatotoxic activities of Bosentan.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Bosentan.]
[A10BB07, glipizide, Bosentan may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the antihypertensive activities of Bosentan.]
[C05AE01, nitroglycerin, Bosentan may increase the hypotensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Bosentan.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be increased when combined with Bosentan.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Bosentan.]
[C07AB09, esmolol, Esmolol may increase the hypotensive activities of Bosentan.]
[B01AA12, fluindione, The metabolism of Fluindione can be increased when combined with Bosentan.]
[C09AA09, fosinopril, Fosinopril may increase the hypotensive activities of Bosentan.]
[S01EX01, guanethidine, Bosentan may increase the hypotensive activities of Guanethidine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Bosentan.]
[N01AB01, halothane, The metabolism of Halothane can be increased when combined with Bosentan.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Bosentan.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin aspart.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Bosentan.]
[C09CA01, losartan, Bosentan may decrease the excretion rate of Losartan which could result in a higher serum level.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Bosentan.]
[A07EC02, mesalamine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Mesalazine.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be increased when combined with Bosentan.]
[R03CC05, hexoprenaline, Hexoprenaline may decrease the antihypertensive activities of Bosentan.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be increased when combined with Bosentan.]
[C08CA10, nilvadipine, The metabolism of Bosentan can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The therapeutic efficacy of Bosentan can be decreased when used in combination with Nimesulide.]
[C09AA04, perindopril, Bosentan may increase the hypotensive activities of Perindopril.]
[C02DB02, hydralazine, Bosentan may increase the hypotensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Hydroflumethiazide.]
[G04BD06, propiverine, Propiverine may decrease the antihypertensive activities of Bosentan.]
[C02AC06, rilmenidine, Rilmenidine may decrease the antihypertensive activities of Bosentan.]
[R02AX02, ibuprofen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Ibuprofen.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be increased when combined with Bosentan.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Bosentan.]
[N01AH03, sufentanil, Sufentanil may decrease the antihypertensive activities of Bosentan.]
[N06AA02, imipramine, Imipramine may decrease the antihypertensive activities of Bosentan.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Bosentan.]
[M03BX02, tizanidine, Tizanidine may increase the hypotensive activities of Bosentan.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Bosentan.]
[S01BC01, indomethacin, Bosentan may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[C02CA02, indoramin, Indoramin may decrease the antihypertensive activities of Bosentan.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Bosentan.]
[R01AA02, cyclopentamine, The risk or severity of adverse effects can be increased when Bosentan is combined with Cyclopentamine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be increased when used in combination with Bosentan.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be increased when combined with Bosentan.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be increased when used in combination with Bosentan.]
[C10AA06, cerivastatin, Bosentan may decrease the excretion rate of Cerivastatin which could result in a higher serum level.]
[C07AA01, alprenolol, Bosentan may increase the hypotensive activities of Alprenolol.]
[N06AA13, iprindole, Iprindole may decrease the antihypertensive activities of Bosentan.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Bosentan.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Bosentan.]
[S01EC03, dorzolamide, Bosentan may increase the hypotensive activities of Dorzolamide.]
[P01AX06, atovaquone, The metabolism of Bosentan can be decreased when combined with Atovaquone.]
[R03CC06, isoetharine, Isoetharine may decrease the antihypertensive activities of Bosentan.]
[C09AA16, imidapril, Bosentan may increase the hypotensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may decrease the antihypertensive activities of Bosentan.]
[J04AC01, isoniazid, The metabolism of Bosentan can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, Isoprenaline may decrease the antihypertensive activities of Bosentan.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be increased when used in combination with Bosentan.]
[C01DA14, isosorbide mononitrate, Bosentan may increase the vasodilatory activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, Isosorbide dinitrate may increase the hypotensive activities of Bosentan.]
[C04AA01, isoxsuprine, Isoxsuprine may decrease the antihypertensive activities of Bosentan.]
[P02CF01, ivermectin, The excretion of Bosentan can be decreased when combined with Ivermectin.]
[L04AC07, tocilizumab, The metabolism of Bosentan can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be increased when combined with Bosentan.]
[C02KD01, ketanserin, Bosentan may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be increased when combined with Bosentan.]
[J02AB02, ketoconazole, The metabolism of Bosentan can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Bosentan can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The metabolism of Bosentan can be decreased when combined with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bosentan.]
[L04AA24, abatacept, The metabolism of Bosentan can be increased when combined with Abatacept.]
[C01CA22, arbutamine, Arbutamine may decrease the antihypertensive activities of Bosentan.]
[N04BC09, rotigotine, Rotigotine may decrease the antihypertensive activities of Bosentan.]
[M01AE11, tiaprofenic acid, The therapeutic efficacy of Bosentan can be decreased when used in combination with Tiaprofenic acid.]
[C07AG01, labetalol, Bosentan may increase the hypotensive activities of Labetalol.]
[C02AA05, deserpidine, Bosentan may increase the hypotensive activities of Deserpidine.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be increased when combined with Bosentan.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the hypotensive activities of Bosentan.]
[G03AD01, levonorgestrel, The serum concentration of Levonorgestrel can be decreased when it is combined with Bosentan.]
[N04BA01, levodopa, Levodopa may increase the hypotensive activities of Bosentan.]
[N06BA13, armodafinil, The metabolism of Bosentan can be decreased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be increased when combined with Bosentan.]
[C03DB01, amiloride, Amiloride may increase the hypotensive activities of Bosentan.]
[N02CA07, lisuride, Lisuride may decrease the antihypertensive activities of Bosentan.]
[N06AA07, lofepramine, Lofepramine may decrease the antihypertensive activities of Bosentan.]
[C10AA02, lovastatin, The serum concentration of Lovastatin can be decreased when it is combined with Bosentan.]
[G03DC03, lynestrenol, The serum concentration of Lynestrenol can be decreased when it is combined with Bosentan.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Bosentan.]
[L01EA03, nilotinib, The metabolism of Bosentan can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the hypotensive activities of Bosentan.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Bosentan is combined with Mecamylamine.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Bosentan can be decreased when used in combination with Meclofenamic acid.]
[N02AB02, meperidine, The metabolism of Meperidine can be increased when combined with Bosentan.]
[C01CA11, mephentermine, Mephentermine may decrease the antihypertensive activities of Bosentan.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be increased when combined with Bosentan.]
[N05AX13, paliperidone, Paliperidone may decrease the antihypertensive activities of Bosentan.]
[C01CA09, metaraminol, Metaraminol may decrease the antihypertensive activities of Bosentan.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be increased when used in combination with Bosentan.]
[N07BC02, methadone, The metabolism of Methadone can be increased when combined with Bosentan.]
[N06BA03, methamphetamine, Metamfetamine may decrease the antihypertensive activities of Bosentan.]
[S01EC05, methazolamide, Methazolamide may increase the hypotensive activities of Bosentan.]
[G02CB05, metergoline, Metergoline may decrease the antihypertensive activities of Bosentan.]
[H03BB02, methimazole, The metabolism of Bosentan can be decreased when combined with Methimazole.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Bosentan is combined with Methotrexate.]
[N05AA02, methotrimeprazine, Methotrimeprazine may decrease the antihypertensive activities of Bosentan.]
[C01CA10, methoxamine, Methoxamine may decrease the antihypertensive activities of Bosentan.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be increased when combined with Bosentan.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, Bosentan may increase the hypotensive activities of Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the hypotensive activities of Bosentan.]
[G02AB01, methylergonovine, Methylergometrine may decrease the antihypertensive activities of Bosentan.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Bosentan.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Bosentan.]
[N02CA04, methysergide, The metabolism of Methysergide can be increased when combined with Bosentan.]
[C03BA08, metolazone, Metolazone may increase the hypotensive activities of Bosentan.]
[C07AB02, metoprolol, Metoprolol may increase the hypotensive activities of Bosentan.]
[P01AB01, metronidazole, The metabolism of Bosentan can be decreased when combined with Metronidazole.]
[N06AX03, mianserin, Mianserin may decrease the antihypertensive activities of Bosentan.]
[S02AA13, miconazole, The metabolism of Bosentan can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Aminophenazone.]
[C01CA17, midodrine, Midodrine may decrease the antihypertensive activities of Bosentan.]
[G03XB01, mifepristone, The serum concentration of Mifepristone can be decreased when it is combined with Bosentan.]
[C09CA03, valsartan, The metabolism of Valsartan can be increased when combined with Bosentan.]
[D11AX01, minoxidil, Minoxidil may increase the hypotensive activities of Bosentan.]
[L01XX23, mitotane, The metabolism of Bosentan can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the antihypertensive activities of Bosentan.]
[L03AC01, aldesleukin, Aldesleukin may increase the hypotensive activities of Bosentan.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Bosentan.]
[C01BD01, amiodarone, The metabolism of Bosentan can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be increased when combined with Bosentan.]
[N02AA01, morphine, Morphine may increase the hypotensive activities of Bosentan.]
[L04AB05, certolizumab pegol, The metabolism of Bosentan can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The excretion of Bosentan can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Bosentan.]
[P01BA06, amodiaquine, The metabolism of Bosentan can be decreased when combined with Amodiaquine.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Bosentan is combined with Silodosin.]
[N06AA17, amoxapine, Amoxapine may decrease the antihypertensive activities of Bosentan.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be increased when combined with Bosentan.]
[C07AA12, nadolol, Bosentan may increase the hypotensive activities of Nadolol.]
[N04BC04, ropinirole, Ropinirole may increase the hypotensive activities of Bosentan.]
[V03AB15, naloxone, The metabolism of Bosentan can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Bosentan can be increased when combined with Anakinra.]
[S01GA01, naphazoline, Naphazoline may decrease the antihypertensive activities of Bosentan.]
[N06BA01, amphetamine, Amphetamine may decrease the antihypertensive activities of Bosentan.]
[M02AA12, naproxen, Bosentan may decrease the excretion rate of Naproxen which could result in a higher serum level.]
[A10BG01, troglitazone, The metabolism of Bosentan can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Duloxetine can be increased when combined with Bosentan.]
[N04BX01, tolcapone, Tolcapone may increase the hypotensive activities of Bosentan.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Bosentan.]
[N01AH06, remifentanil, Remifentanil may decrease the antihypertensive activities of Bosentan.]
[A10BX02, repaglinide, Bosentan may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C01CX08, levosimendan, Levosimendan may increase the hypotensive activities of Bosentan.]
[N05AX14, iloperidone, Iloperidone may decrease the antihypertensive activities of Bosentan.]
[J02AA01, amphotericin B, Amphotericin B may increase the hypotensive activities of Bosentan.]
[N06AX23, desvenlafaxine, The metabolism of Bosentan can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, Bosentan may decrease the excretion rate of Telmisartan which could result in a higher serum level.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Bosentan.]
[C08CA04, nicardipine, The metabolism of Bosentan can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may decrease the antihypertensive activities of Bosentan.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be increased when combined with Bosentan.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Bosentan is combined with Nicotine.]
[C08CA05, nifedipine, Bosentan may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The therapeutic efficacy of Bosentan can be decreased when used in combination with Niflumic acid.]
[V03AB22, amyl nitrite, Amyl Nitrite may increase the hypotensive activities of Bosentan.]
[C08CA06, nimodipine, Nimodipine may increase the hypotensive activities of Bosentan.]
[C08CA07, nisoldipine, Nisoldipine may increase the hypotensive activities of Bosentan.]
[C08CA08, nitrendipine, Bosentan may decrease the excretion rate of Nitrendipine which could result in a higher serum level.]
[R07AX01, nitric oxide, Nitric Oxide may increase the hypotensive activities of Bosentan.]
[J01XE01, nitrofurantoin, Bosentan may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may increase the hypotensive activities of Bosentan.]
[C02DD01, nitroprusside, Nitroprusside may increase the hypotensive activities of Bosentan.]
[N01AX13, nitrous oxide, Nitrous oxide may decrease the antihypertensive activities of Bosentan.]
[C01CA03, norepinephrine, Norepinephrine may decrease the antihypertensive activities of Bosentan.]
[G03DC02, norethindrone, The serum concentration of Norethisterone can be decreased when it is combined with Bosentan.]
[G03AC07, norgestrienone, The serum concentration of Norgestrienone can be decreased when it is combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Bosentan.]
[R05DA07, noscapine, The metabolism of Bosentan can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, Nylidrin may decrease the antihypertensive activities of Bosentan.]
[G01AA01, nystatin, The excretion of Bosentan can be decreased when combined with Nystatin.]
[S02AA16, ofloxacin, Bosentan may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[L04AC04, rilonacept, The metabolism of Bosentan can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be increased when combined with Bosentan.]
[N06AA05, opipramol, Opipramol may decrease the antihypertensive activities of Bosentan.]
[R03CB03, metaproterenol, Orciprenaline may decrease the antihypertensive activities of Bosentan.]
[G04CA02, tamsulosin, Tamsulosin may increase the hypotensive activities of Bosentan.]
[C01AC01, ouabain, The excretion of Bosentan can be decreased when combined with Ouabain.]
[A14AA08, oxandrolone, The metabolism of Bosentan can be decreased when combined with Oxandrolone.]
[C07AA02, oxprenolol, Bosentan may increase the hypotensive activities of Oxprenolol.]
[C01DX03, oxyfedrine, Oxyfedrine may decrease the antihypertensive activities of Bosentan.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Bosentan can be decreased when used in combination with Oxymetazoline.]
[S01BC02, oxyphenbutazone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Oxyphenbutazone.]
[V04CH30, 4-aminohippuric acid, The excretion of Bosentan can be decreased when combined with Aminohippuric acid.]
[N05AH05, asenapine, Asenapine may decrease the antihypertensive activities of Bosentan.]
[G03DB06, chlormadinone, The serum concentration of Chlormadinone can be decreased when it is combined with Bosentan.]
[G04BE02, papaverine, Papaverine may increase the hypotensive activities of Bosentan.]
[C02KC01, pargyline, Pargyline may increase the hypotensive activities of Bosentan.]
[C07AA23, penbutolol, Bosentan may increase the hypotensive activities of Penbutolol.]
[S01AA14, penicillin G, Bosentan may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, The metabolism of Bosentan can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Bosentan.]
[N04BC02, pergolide, Pergolide may decrease the antihypertensive activities of Bosentan.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be increased when combined with Bosentan.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Bosentan.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be increased when used in combination with Bosentan.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be increased when combined with Bosentan.]
[C04AX02, phenoxybenzamine, Phenoxybenzamine may decrease the antihypertensive activities of Bosentan.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be increased when combined with Bosentan.]
[A08AA01, phentermine, Phentermine may decrease the antihypertensive activities of Bosentan.]
[V03AB36, phentolamine, Phentolamine may decrease the antihypertensive activities of Bosentan.]
[M02AA01, phenylbutazone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Phenylbutazone.]
[S01GA05, phenylephrine, Phenylephrine may decrease the antihypertensive activities of Bosentan.]
[R01BA01, phenylpropanolamine, Phenylpropanolamine may decrease the antihypertensive activities of Bosentan.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be increased when combined with Bosentan.]
[L04AB06, golimumab, The metabolism of Bosentan can be increased when combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Bosentan.]
[C08CX01, mibefradil, Bosentan may increase the hypotensive activities of Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Bosentan.]
[C07AA03, pindolol, Bosentan may increase the hypotensive activities of Pindolol.]
[C10AA05, atorvastatin, The serum concentration of Atorvastatin can be decreased when it is combined with Bosentan.]
[J05AE01, saquinavir, The serum concentration of Bosentan can be increased when it is combined with Saquinavir.]
[C09CA02, eprosartan, Bosentan may increase the hypotensive activities of Eprosartan.]
[S01BC06, piroxicam, The therapeutic efficacy of Bosentan can be decreased when used in combination with Piroxicam.]
[N02CX01, pizotyline, Pizotifen may decrease the antihypertensive activities of Bosentan.]
[J05AG02, delavirdine, The metabolism of Bosentan can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be increased when combined with Bosentan.]
[A10BG02, rosiglitazone, Bosentan may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[A03AE01, alosetron, The metabolism of Alosetron can be increased when combined with Bosentan.]
[L04AC08, canakinumab, The metabolism of Bosentan can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Bosentan can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be increased when used in combination with Bosentan.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin lispro.]
[C10AA08, pitavastatin, Bosentan may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C07AB01, practolol, Bosentan may increase the hypotensive activities of Practolol.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Bosentan.]
[P01BA03, primaquine, The metabolism of Bosentan can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Bosentan can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Bosentan can be decreased when combined with Probenecid.]
[S01HA05, procaine, Procaine may increase the hypotensive activities of Bosentan.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Bosentan.]
[C10AB05, fenofibrate, Bosentan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, The serum concentration of Progesterone can be decreased when it is combined with Bosentan.]
[N05AA03, promazine, The metabolism of Promazine can be increased when combined with Bosentan.]
[R06AD02, promethazine, The metabolism of Bosentan can be decreased when combined with Promethazine.]
[C01BC03, propafenone, Propafenone may decrease the antihypertensive activities of Bosentan.]
[N05AC01, periciazine, Periciazine may decrease the antihypertensive activities of Bosentan.]
[N05CM06, propiomazine, Propiomazine may decrease the antihypertensive activities of Bosentan.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Bosentan.]
[N01AX10, propofol, The metabolism of Propofol can be increased when combined with Bosentan.]
[C07AA05, propranolol, Bosentan may increase the hypotensive activities of Propranolol.]
[N02CC04, rizatriptan, Rizatriptan may decrease the antihypertensive activities of Bosentan.]
[B01AC09, epoprostenol, Epoprostenol may increase the hypotensive activities of Bosentan.]
[R03DC03, montelukast, The metabolism of Montelukast can be increased when combined with Bosentan.]
[N06AA11, protriptyline, Protriptyline may decrease the antihypertensive activities of Bosentan.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the antihypertensive activities of Bosentan.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Bosentan.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Bosentan.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be increased when used in combination with Bosentan.]
[C02AA01, rescinnamine, Rescinnamine may decrease the antihypertensive activities of Bosentan.]
[C02AA02, reserpine, The risk or severity of liver damage can be increased when Reserpine is combined with Bosentan.]
[J04AB02, rifampin, The serum concentration of Bosentan can be decreased when it is combined with Rifampicin.]
[R03AC05, rimiterol, Rimiterol may decrease the antihypertensive activities of Bosentan.]
[G02CA01, ritodrine, Ritodrine may decrease the antihypertensive activities of Bosentan.]
[J01FA06, roxithromycin, The excretion of Bosentan can be decreased when combined with Roxithromycin.]
[N02BA05, salicylamide, The therapeutic efficacy of Bosentan can be decreased when used in combination with Salicylamide.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Bosentan can be decreased when used in combination with Salicylic acid.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Bosentan.]
[L01FA03, obinutuzumab, Bosentan may increase the hypotensive activities of Obinutuzumab.]
[C07AA07, sotalol, Sotalol may increase the hypotensive activities of Bosentan.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Bosentan.]
[C03DA01, spironolactone, Bosentan may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[S02DA03, antipyrine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Antipyrine.]
[G03XB02, ulipristal, The serum concentration of Ulipristal can be decreased when it is combined with Bosentan.]
[B01AD01, streptokinase, Streptokinase may increase the hypotensive activities of Bosentan.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Bosentan.]
[S01AB01, sulfamethizole, The metabolism of Bosentan can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, Bosentan may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[J01EC03, sulfamoxole, The metabolism of Bosentan can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Bosentan can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, Bosentan may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Bosentan.]
[M01AB02, sulindac, The therapeutic efficacy of Bosentan can be decreased when used in combination with Sulindac.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Bosentan.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be increased when used in combination with Bosentan.]
[M01AX04, apazone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Azapropazone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Bosentan.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Bosentan.]
[R03CC03, terbutaline, Terbutaline may decrease the antihypertensive activities of Bosentan.]
[G03BA03, testosterone, The metabolism of Testosterone can be increased when combined with Bosentan.]
[N05AE05, lurasidone, Lurasidone may decrease the antihypertensive activities of Bosentan.]
[A04AD10, dronabinol, The metabolism of Dronabinol can be increased when combined with Bosentan.]
[N04BC07, apomorphine, Apomorphine may increase the hypotensive activities of Bosentan.]
[L04AX02, thalidomide, The metabolism of Thalidomide can be increased when combined with Bosentan.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Bosentan.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Bosentan.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Bosentan.]
[N05AB08, thioproperazine, Thioproperazine may decrease the antihypertensive activities of Bosentan.]
[N05AC02, thioridazine, Thioridazine may decrease the antihypertensive activities of Bosentan.]
[G04BE06, moxisylyte, Moxisylyte may decrease the antihypertensive activities of Bosentan.]
[B01AC05, ticlopidine, The metabolism of Bosentan can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, Timolol may increase the hypotensive activities of Bosentan.]
[P01AB02, tinidazole, Bosentan may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Bosentan.]
[M02AX02, tolazoline, Tolazoline may decrease the antihypertensive activities of Bosentan.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Bosentan.]
[M02AA21, tolmetin, The therapeutic efficacy of Bosentan can be decreased when used in combination with Tolmetin.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Bosentan.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypotensive activities of Bosentan.]
[N06AX05, trazodone, Trazodone may decrease the antihypertensive activities of Bosentan.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be increased when combined with Bosentan.]
[C03DB02, triamterene, Triamterene may increase the hypotensive activities of Bosentan.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Trichlormethiazide.]
[N05AB06, trifluoperazine, Trifluoperazine may decrease the antihypertensive activities of Bosentan.]
[S01ED04, metipranolol, Bosentan may increase the hypotensive activities of Metipranolol.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be increased when combined with Bosentan.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Bosentan is combined with Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be increased when combined with Bosentan.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be increased when combined with Bosentan.]
[J01FA08, troleandomycin, The metabolism of Bosentan can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, Vilazodone may decrease the antihypertensive activities of Bosentan.]
[C09CA09, azilsartan medoxomil, Bosentan may increase the hypotensive activities of Azilsartan medoxomil.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be increased when combined with Bosentan.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Bosentan.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be increased when combined with Bosentan.]
[J05AP03, boceprevir, The metabolism of Bosentan can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Bosentan can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Bosentan.]
[R03AC18, indacaterol, Indacaterol may decrease the antihypertensive activities of Bosentan.]
[B01AC24, ticagrelor, The metabolism of Bosentan can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Bosentan can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Bosentan can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Bosentan.]
[C04AX07, vincamine, Bosentan may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Bosentan.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Bosentan.]
[B01AA03, warfarin, The metabolism of Warfarin can be increased when combined with Bosentan.]
[S01AA13, fusidic acid, The metabolism of Bosentan can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Bosentan.]
[C03BA10, xipamide, Bosentan may increase the hypotensive activities of Xipamide.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be increased when combined with Bosentan.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be increased when combined with Bosentan.]
[J05AE02, indinavir, The serum concentration of Bosentan can be increased when it is combined with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Bosentan.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Bosentan.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Bosentan.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be increased when combined with Bosentan.]
[N05AE04, ziprasidone, Ziprasidone may increase the antihypertensive activities of Bosentan.]
[G03AC10, drospirenone, The serum concentration of Drospirenone can be decreased when it is combined with Bosentan.]
[N02BA01, aspirin, The metabolism of Acetylsalicylic acid can be increased when combined with Bosentan.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Bosentan.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be increased when combined with Bosentan.]
[C07AB03, atenolol, Bosentan may decrease the excretion rate of Atenolol which could result in a higher serum level.]
[L01FA01, rituximab, Bosentan may increase the hypotensive activities of Rituximab.]
[J02AC03, voriconazole, The metabolism of Bosentan can be decreased when combined with Voriconazole.]
[S01FA01, atropine, Bosentan may decrease the excretion rate of Atropine which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be increased when combined with Bosentan.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Bosentan.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Bosentan.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Bosentan.]
[G04BD12, mirabegron, Mirabegron may decrease the antihypertensive activities of Bosentan.]
[V03AX03, cobicistat, The serum concentration of Bosentan can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Bosentan can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Bosentan can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Bosentan.]
[L04AA31, teriflunomide, The excretion of Bosentan can be decreased when combined with Teriflunomide.]
[C01CA18, octopamine, Octopamine may decrease the antihypertensive activities of Bosentan.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Bosentan.]
[J05AE04, nelfinavir, The serum concentration of Bosentan can be increased when it is combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Bosentan.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Bosentan.]
[C08CA13, lercanidipine, Lercanidipine may increase the hypotensive activities of Bosentan.]
[N06DA02, donepezil, The metabolism of Donepezil can be increased when combined with Bosentan.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Bosentan.]
[N02CC03, zolmitriptan, Zolmitriptan may decrease the antihypertensive activities of Bosentan.]
[N01AA01, ethyl ether, Diethyl ether may decrease the antihypertensive activities of Bosentan.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be increased when combined with Bosentan.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be increased when combined with Bosentan.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Bosentan.]
[B01AF02, apixaban, The metabolism of Apixaban can be increased when combined with Bosentan.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Bosentan.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Bosentan.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Bosentan.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be increased when combined with Bosentan.]
[N02BA10, benorilate, The therapeutic efficacy of Bosentan can be decreased when used in combination with Benorilate.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bosentan.]
[M04AB03, benzbromarone, Bosentan may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin detemir.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be increased when used in combination with Bosentan.]
[J02AX04, caspofungin, The excretion of Bosentan can be decreased when combined with Caspofungin.]
[M01AH01, celecoxib, The therapeutic efficacy of Bosentan can be decreased when used in combination with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may decrease the antihypertensive activities of Bosentan.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Bosentan resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Bosentan.]
[L01EC02, dabrafenib, The serum concentration of Bosentan can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Benzydamine.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Bosentan.]
[C08EA02, bepridil, Bosentan may increase the hypotensive activities of Bepridil.]
[C02KX05, riociguat, Bosentan may increase the hypotensive activities of Riociguat.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be increased when used in combination with Bosentan.]
[A05AA03, cholic acid, Bosentan may decrease the excretion rate of Cholic Acid which could result in a higher serum level.]
[C02KX04, macitentan, Bosentan may increase the hypotensive activities of Macitentan.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be increased when combined with Bosentan.]
[G03AC08, etonogestrel, The serum concentration of Etonogestrel can be decreased when it is combined with Bosentan.]
[J05AP05, simeprevir, The metabolism of Bosentan can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Bosentan.]
[C01CA27, droxidopa, Droxidopa may decrease the antihypertensive activities of Bosentan.]
[C07AB04, acebutolol, Bosentan may increase the hypotensive activities of Acebutolol.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be increased when combined with Bosentan.]
[A16AA07, metreleptin, The metabolism of Bosentan can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Bosentan can be increased when combined with Apremilast.]
[S01ED02, betaxolol, Betaxolol may increase the hypotensive activities of Bosentan.]
[C02CC01, bethanidine, Bethanidine may decrease the antihypertensive activities of Bosentan.]
[C10AB02, bezafibrate, The excretion of Bosentan can be decreased when combined with Bezafibrate.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be increased when used in combination with Bosentan.]
[L04AC11, siltuximab, The metabolism of Bosentan can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be increased when combined with Bosentan.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be increased when combined with Bosentan.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be increased when combined with Bosentan.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Bosentan.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bosentan.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be increased when combined with Bosentan.]
[S01EE02, unoprostone, Bosentan may increase the hypotensive activities of Unoprostone.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be increased when combined with Bosentan.]
[J01XA05, oritavancin, The metabolism of Bosentan can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, Acepromazine may decrease the antihypertensive activities of Bosentan.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be increased when used in combination with Bosentan.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be increased when combined with Bosentan.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Bosentan.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Bosentan.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be increased when combined with Bosentan.]
[N06AX11, mirtazapine, Mirtazapine may decrease the antihypertensive activities of Bosentan.]
[L04AC10, secukinumab, The metabolism of Bosentan can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Bosentan.]
[L01EX08, lenvatinib, The risk or severity of liver damage can be increased when Bosentan is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Bosentan.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be increased when combined with Bosentan.]
[J05AP06, asunaprevir, The serum concentration of Bosentan can be increased when it is combined with Asunaprevir.]
[A07DA06, eluxadoline, The excretion of Bosentan can be decreased when combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may decrease the antihypertensive activities of Bosentan.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Bosentan.]
[A04AD14, rolapitant, The metabolism of Rolapitant can be increased when combined with Bosentan.]
[G02CX02, flibanserin, Flibanserin may decrease the antihypertensive activities of Bosentan.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be increased when combined with Bosentan.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be increased when used in combination with Bosentan.]
[M02AA25, aceclofenac, The therapeutic efficacy of Bosentan can be decreased when used in combination with Aceclofenac.]
[M01AB11, acemetacin, The therapeutic efficacy of Bosentan can be decreased when used in combination with Acemetacin.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin degludec.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be increased when combined with Bosentan.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Bosentan.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be increased when combined with Bosentan.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Bosentan.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be increased when combined with Bosentan.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Bosentan.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Bosentan.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Bosentan.]
[B01AC27, selexipag, Bosentan may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Bosentan.]
[G04CA01, alfuzosin, Alfuzosin may increase the hypotensive activities of Bosentan.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be increased when combined with Bosentan.]
[M01AE16, alminoprofen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Alminoprofen.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be increased when combined with Bosentan.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Bosentan.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Bosentan.]
[N06AA19, amineptin, Amineptine may decrease the antihypertensive activities of Bosentan.]
[C08CA01, amlodipine, Amlodipine may increase the hypotensive activities of Bosentan.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Bosentan.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Bosentan is combined with Obeticholic acid.]
[C03CA02, bumetanide, Bumetanide may increase the hypotensive activities of Bosentan.]
[N01BB01, bupivacaine, Bupivacaine may increase the hypotensive activities of Bosentan.]
[C07AA19, bupranolol, Bosentan may increase the hypotensive activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be increased when combined with Bosentan.]
[N05BE01, buspirone, Buspirone may decrease the antihypertensive activities of Bosentan.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Bosentan.]
[L01XX27, arsenic trioxide, Arsenic trioxide may increase the hypotensive activities of Bosentan.]
[P01BE02, artemether, The metabolism of Artemether can be increased when combined with Bosentan.]
[S01GX07, azelastine, The metabolism of Azelastine can be increased when combined with Bosentan.]
[L01XK03, rucaparib, The metabolism of Bosentan can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be increased when combined with Bosentan.]
[L01EF02, ribociclib, The metabolism of Bosentan can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The therapeutic efficacy of Bosentan can be decreased when used in combination with Balsalazide.]
[R03CC12, bambuterol, Bambuterol may decrease the antihypertensive activities of Bosentan.]
[C09AA07, benazepril, Benazepril may increase the hypotensive activities of Bosentan.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be increased when used in combination with Bosentan.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Bosentan.]
[J05AE09, tipranavir, The serum concentration of Bosentan can be increased when it is combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Bosentan can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Bosentan can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Bosentan.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Bosentan.]
[J01MA23, delafloxacin, The metabolism of Bosentan can be increased when combined with Delafloxacin.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be increased when combined with Bosentan.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Bosentan.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Bosentan.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Bosentan.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Bosentan.]
[C07AB07, bisoprolol, Bosentan may increase the hypotensive activities of Bisoprolol.]
[R03AC17, bitolterol, Bitolterol may decrease the antihypertensive activities of Bosentan.]
[J05AG03, efavirenz, The metabolism of Bosentan can be decreased when combined with Efavirenz.]
[C01DX19, nesiritide, Nesiritide may increase the hypotensive activities of Bosentan.]
[V03AB23, acetylcysteine, The excretion of Bosentan can be decreased when combined with Acetylcysteine.]
[R03BA02, budesonide, Bosentan may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Bosentan.]
[M01AB07, bumadizone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Bosentan.]
[J05AX18, letermovir, The risk or severity of liver damage can be increased when Bosentan is combined with Letermovir.]
[N06AA15, butriptyline, Butriptyline may decrease the antihypertensive activities of Bosentan.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be increased when used in combination with Bosentan.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Bosentan.]
[C09AA01, captopril, Bosentan may increase the hypotensive activities of Captopril.]
[L02BB05, apalutamide, The metabolism of Bosentan can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be increased when combined with Bosentan.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be increased when combined with Bosentan.]
[B02BX09, fostamatinib, Fostamatinib may increase the antihypertensive activities of Bosentan.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be increased when combined with Bosentan.]
[B02BX08, avatrombopag, The metabolism of Bosentan can be increased when combined with Avatrombopag.]
[C07AB08, celiprolol, Bosentan may increase the hypotensive activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Bosentan can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Bosentan can be decreased when combined with Stiripentol.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Bosentan.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Bosentan.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Bosentan.]
[N01BA04, chloroprocaine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Chloroprocaine.]
[M01AC05, lornoxicam, The therapeutic efficacy of Bosentan can be decreased when used in combination with Lornoxicam.]
[L04AA39, emapalumab, The metabolism of Bosentan can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Bosentan.]
[C09AA08, cilazapril, Bosentan may increase the hypotensive activities of Cilazapril.]
[A03FA08, cinitapride, Cinitapride may decrease the antihypertensive activities of Bosentan.]
[S01ED05, carteolol, Carteolol may increase the hypotensive activities of Bosentan.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be increased when combined with Bosentan.]
[N06AX27, esketamine, The metabolism of Esketamine can be increased when combined with Bosentan.]
[L04AA42, siponimod, The therapeutic efficacy of Siponimod can be decreased when used in combination with Bosentan.]
[J01FA09, clarithromycin, The serum concentration of 14-OH-Clarithromycin, an active metabolite of Bosentan, can be increased when used in combination with Clarithromycin.]
[N06BA14, solriamfetol, Solriamfetol may decrease the antihypertensive activities of Bosentan.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Bosentan.]
[C09CA06, candesartan, The metabolism of Candesartan can be increased when combined with Bosentan.]
[L04AB01, etanercept, The metabolism of Bosentan can be increased when combined with Etanercept.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Bosentan resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EM03, alpelisib, The serum concentration of Bosentan can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, Bosentan may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[L02BB06, darolutamide, The serum concentration of Darolutamide can be decreased when it is combined with Bosentan.]
[L01EX15, pexidartinib, Bosentan may increase the hepatotoxic activities of Pexidartinib.]
[C03BX03, cicletanine, Bosentan may increase the hypotensive activities of Cicletanine.]
[L01EJ02, fedratinib, The excretion of Bosentan can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Bosentan.]
[N07XX11, pitolisant, The serum concentration of Bosentan can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Bosentan.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Bosentan.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be increased when combined with Bosentan.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may decrease the antihypertensive activities of Bosentan.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin pork.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Bosentan.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be decreased when it is combined with Bosentan.]
[G03DB05, demegestone, The serum concentration of Demegestone can be decreased when it is combined with Bosentan.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Bosentan.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Bosentan.]
[G03AC09, desogestrel, The serum concentration of Desogestrel can be decreased when it is combined with Bosentan.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be decreased when it is combined with Bosentan.]
[N03AX25, cenobamate, The serum concentration of Bosentan can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be decreased when it is combined with Bosentan.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be increased when combined with Bosentan.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Bosentan.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Bosentan.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Bosentan.]
[M01AX21, diacetylrhein, The metabolism of Bosentan can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Bosentan.]
[C10AX15, bempedoic acid, The excretion of Bosentan can be decreased when combined with Bempedoic acid.]
[J05AE05, amprenavir, The serum concentration of Bosentan can be increased when it is combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may decrease the antihypertensive activities of Bosentan.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Bosentan.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be decreased when it is combined with Bosentan.]
[G03DB08, dienogest, The serum concentration of Dienogest can be decreased when it is combined with Bosentan.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be increased when combined with Bosentan.]
[M01AH02, rofecoxib, The therapeutic efficacy of Bosentan can be decreased when used in combination with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Bexarotene can be increased when combined with Bosentan.]
[C08CA16, clevidipine, The metabolism of Bosentan can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Bosentan.]
[C02AA06, methoserpidine, Bosentan may increase the hypotensive activities of Methoserpidine.]
[L01EN02, pemigatinib, The metabolism of Pemigatinib can be increased when combined with Bosentan.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Bosentan.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Bosentan.]
[N04BX04, opicapone, Opicapone may increase the hypotensive activities of Bosentan.]
[C01CA14, dopexamine, Dopexamine may decrease the antihypertensive activities of Bosentan.]
[M01AC04, droxicam, The therapeutic efficacy of Bosentan can be decreased when used in combination with Droxicam.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Bosentan.]
[M02AA27, dexketoprofen, The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bosentan.]
[L01XX69, lurbinectedin, The serum concentration of Lurbinectedin can be decreased when it is combined with Bosentan.]
[C08CA17, levamlodipine, Bosentan may increase the hypotensive activities of Levamlodipine.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Bosentan.]
[J05AX29, fostemsavir, The excretion of Bosentan can be decreased when combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Proguanil can be increased when combined with Bosentan.]
[L01FX15, belantamab mafodotin, Bosentan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The serum concentration of Bosentan can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be decreased when it is combined with Bosentan.]
[L01EX23, pralsetinib, The risk or severity of liver damage can be increased when Bosentan is combined with Pralsetinib.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Chlorothiazide.]
[N05AA01, chlorpromazine, The metabolism of Chlorpromazine can be increased when combined with Bosentan.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Bosentan.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the hypotensive activities of Bosentan.]
[V04CK02, cholecystokinin, The excretion of Bosentan can be decreased when combined with Cholecystokinin.]
[N02BA07, ethenzamide, The therapeutic efficacy of Bosentan can be decreased when used in combination with Ethenzamide.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Bosentan resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03DC06, ethynodiol, The serum concentration of Etynodiol can be decreased when it is combined with Bosentan.]
[M01AB08, etodolac, The therapeutic efficacy of Bosentan can be decreased when used in combination with Etodolac.]
[M02AA06, etofenamate, The therapeutic efficacy of Bosentan can be decreased when used in combination with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Bosentan can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Bosentan can be decreased when combined with Lonafarnib.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Bosentan.]
[L04AD03, voclosporin, The metabolism of Voclosporin can be increased when combined with Bosentan.]
[P03AX07, abametapir, The serum concentration of Bosentan can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, Vericiguat may increase the hypotensive activities of Bosentan.]
[L01EX21, tepotinib, The metabolism of Bosentan can be decreased when combined with Tepotinib.]
[N03AX10, felbamate, The metabolism of Bosentan can be decreased when combined with Felbamate.]
[M01AE05, fenbufen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Fenbufen.]
[C01CA19, fenoldopam, Bosentan may increase the hypotensive activities of Fenoldopam.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Bosentan.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Bosentan.]
[S01JA01, fluorescein, Bosentan may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be increased when combined with Bosentan.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin human.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Bosentan.]
[N01AB05, trichloroethylene, Trichloroethylene may decrease the antihypertensive activities of Bosentan.]
[L03AB10, peginterferon alfa-2b, The metabolism of Bosentan can be increased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Bosentan may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The risk or severity of liver damage can be increased when Cimetidine is combined with Bosentan.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be increased when combined with Bosentan.]
[L01XX73, sotorasib, The serum concentration of Bosentan can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Bosentan.]
[S03AA07, ciprofloxacin, The metabolism of Bosentan can be decreased when combined with Ciprofloxacin.]
[J02AX07, ibrexafungerp, The serum concentration of Ibrexafungerp can be decreased when it is combined with Bosentan.]
[C03DA05, finerenone, The therapeutic efficacy of Finerenone can be decreased when used in combination with Bosentan.]
[L04AA48, belumosudil, The excretion of Bosentan can be decreased when combined with Belumosudil.]
[N02CD07, atogepant, The serum concentration of Atogepant can be decreased when it is combined with Bosentan.]
[M01AG01, mefenamic acid, The therapeutic efficacy of Bosentan can be decreased when used in combination with Mefenamic acid.]
[A10BB12, glimepiride, Bosentan may decrease the excretion rate of Glimepiride which could result in a higher serum level.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Bosentan.]
[R03CC13, clenbuterol, Clenbuterol may decrease the antihypertensive activities of Bosentan.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Bosentan.]
[N06AX25, St. John's wort extract, The metabolism of Bosentan can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Bosentan can be decreased when combined with Asciminib.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be increased when combined with Bosentan.]
[B06AX04, mitapivat, The metabolism of Mitapivat can be increased when combined with Bosentan.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the hypotensive activities of Bosentan.]
[L01EJ03, pacritinib, The serum concentration of Pacritinib can be decreased when it is combined with Bosentan.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Bosentan.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Bosentan.]
[S01EA04, clonidine, The risk or severity of hypotension can be increased when Clonidine is combined with Bosentan.]
[C01EB24, mavacamten, The serum concentration of Bosentan can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be increased when used in combination with Bosentan.]
[N03AX27, ganaxolone, The metabolism of Ganaxolone can be increased when combined with Bosentan.]
[A05BA08, glycyrrhizic acid, Bosentan may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be increased when combined with Bosentan.]
[J05AX31, lenacapavir, The metabolism of Lenacapavir can be increased when combined with Bosentan.]
[N05AH02, clozapine, The metabolism of Bosentan can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be increased when used in combination with Bosentan.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Bosentan.]
[H01AC08, somatrogon, The metabolism of Bosentan can be increased when combined with Somatrogon.]
[C02KB01, metyrosine, Bosentan may increase the hypotensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Bosentan can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Proquazone.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Bosentan resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be increased when combined with Bosentan.]
[N01AB07, desflurane, Desflurane may decrease the antihypertensive activities of Bosentan.]
[C04AX28, ifenprodil, Ifenprodil may decrease the antihypertensive activities of Bosentan.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be increased when used in combination with Bosentan.]
[N02BA16, imidazole-2-hydroxybenzoate, The therapeutic efficacy of Bosentan can be decreased when used in combination with Imidazole salicylate.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be increased when used in combination with Bosentan.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Bosentan can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Indobufen.]
[M01AH03, valdecoxib, The therapeutic efficacy of Bosentan can be decreased when used in combination with Valdecoxib.]
[A03AX10, isometheptene, Isometheptene may decrease the antihypertensive activities of Bosentan.]
[N02CC05, almotriptan, Almotriptan may decrease the antihypertensive activities of Bosentan.]
[M01AH04, parecoxib, The therapeutic efficacy of Bosentan can be decreased when used in combination with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Bosentan can be decreased when combined with Itraconazole.]
[M01AA06, kebuzone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Kebuzone.]
[L01EA01, imatinib, Bosentan may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[J02AC04, posaconazole, The metabolism of Bosentan can be decreased when combined with Posaconazole.]
[S01EE04, travoprost, Travoprost may increase the hypotensive activities of Bosentan.]
[S01EE03, bimatoprost, Bosentan may increase the hypotensive activities of Bimatoprost.]
[C08CA09, lacidipine, Bosentan may increase the hypotensive activities of Lacidipine.]
[N07BC04, lofexidine, Lofexidine may decrease the antihypertensive activities of Bosentan.]
[M01AB09, lonazolac, The therapeutic efficacy of Bosentan can be decreased when used in combination with Lonazolac.]
[R06AX13, loratadine, Bosentan may decrease the excretion rate of Loratadine which could result in a higher serum level.]
[M02AA31, loxoprofen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Loxoprofen.]
[C09AA03, lisinopril, Bosentan may increase the hypotensive activities of Lisinopril.]
[C08CA11, manidipine, The metabolism of Bosentan can be decreased when combined with Manidipine.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Bosentan.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the antihypertensive activities of Bosentan.]
[R06AE03, cyclizine, The metabolism of Bosentan can be decreased when combined with Cyclizine.]
[C03DA04, eplerenone, Bosentan may increase the hypotensive activities of Eplerenone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be increased when used in combination with Bosentan.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Bosentan.]
[N06AX07, minaprine, Minaprine may increase the hypotensive activities of Bosentan.]
[S01XA18, cyclosporine, The serum concentration of Bosentan can be increased when it is combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Bosentan.]
[N06BA07, modafinil, The metabolism of Bosentan can be decreased when combined with Armodafinil.]
[C09AA13, moexipril, Bosentan may increase the hypotensive activities of Moexipril.]
[C10AA07, rosuvastatin, The serum concentration of Rosuvastatin can be decreased when it is combined with Bosentan.]
[M02AA02, mofebutazone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Mofebutazone.]
[M01AX22, morniflumate, The therapeutic efficacy of Bosentan can be decreased when used in combination with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Bosentan can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Moxonidine may decrease the antihypertensive activities of Bosentan.]
[G04BE09, vardenafil, Vardenafil may increase the antihypertensive activities of Bosentan.]
[M01AH05, etoricoxib, The therapeutic efficacy of Bosentan can be decreased when used in combination with Etoricoxib.]
[G03XA01, danazol, The metabolism of Bosentan can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dapsone can be increased when combined with Bosentan.]
[L01DB02, daunorubicin, Bosentan may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C02CC04, debrisoquin, Bosentan may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The metabolism of Nabilone can be increased when combined with Bosentan.]
[M01AX01, nabumetone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Nabumetone.]
[C07AB12, nebivolol, Bosentan may increase the hypotensive activities of Nebivolol.]
[N06AX06, nefazodone, The metabolism of Bosentan can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Bosentan may increase the hypotensive activities of Nicorandil.]
[L02BB02, nilutamide, The metabolism of Bosentan can be decreased when combined with Nilutamide.]
[G03DB04, nomegestrol, The serum concentration of Nomegestrol can be decreased when it is combined with Bosentan.]
[C01CA23, theodrenaline, Theodrenaline may decrease the antihypertensive activities of Bosentan.]
[C01CA05, norfenefrine, Norfenefrine may decrease the antihypertensive activities of Bosentan.]
[G04BD08, solifenacin, Solifenacin may decrease the antihypertensive activities of Bosentan.]
[A07EC03, olsalazine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Olsalazine.]
[N06AA01, desipramine, Desipramine may decrease the antihypertensive activities of Bosentan.]
[H01BA02, desmopressin, Desmopressin may decrease the antihypertensive activities of Bosentan.]
[C09XA02, aliskiren, Bosentan may increase the hypotensive activities of Aliskiren.]
[M01AE12, oxaprozin, The therapeutic efficacy of Bosentan can be decreased when used in combination with Oxaprozin.]
[S03BA01, dexamethasone, The metabolism of Bosentan can be increased when combined with Dexamethasone.]
[L04AB04, adalimumab, The metabolism of Bosentan can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the antihypertensive activities of Bosentan.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be increased when combined with Bosentan.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be increased when combined with Bosentan.]
[N06AB05, paroxetine, The metabolism of Bosentan can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be increased when combined with Bosentan.]
[N05BA01, diazepam, The metabolism of Diazepam can be increased when combined with Bosentan.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Bosentan.]
[N06AA08, dibenzepin, Dibenzepin may decrease the antihypertensive activities of Bosentan.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the hypotensive activities of Bosentan.]
[S01BC03, diclofenac, Bosentan may decrease the excretion rate of Diclofenac which could result in a higher serum level.]
[C02DG01, pinacidil, Bosentan may increase the hypotensive activities of Pinacidil.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Bosentan.]
[N05AD05, pipamperone, Pipamperone may increase the hypotensive activities of Bosentan.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Bosentan.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Bosentan.]
[R03CC07, pirbuterol, Pirbuterol may decrease the antihypertensive activities of Bosentan.]
[A08AA03, diethylpropion, Diethylpropion may decrease the antihypertensive activities of Bosentan.]
[L02AA01, diethylstilbestrol, The serum concentration of Diethylstilbestrol can be decreased when it is combined with Bosentan.]
[C08CA03, isradipine, Bosentan may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[N02BA11, diflunisal, The therapeutic efficacy of Bosentan can be decreased when used in combination with Diflunisal.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be increased when combined with Bosentan.]
[C01AA05, digoxin, Bosentan may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Bosentan may increase the hypotensive activities of Dihydralazine.]
[C10AX09, ezetimibe, Bosentan may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Bosentan may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Bosentan.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be increased when combined with Bosentan.]
[J05AE08, atazanavir, The serum concentration of Atazanavir can be decreased when it is combined with Bosentan.]
[B01AC21, treprostinil, Treprostinil may increase the hypotensive activities of Bosentan.]
[C08DB01, diltiazem, The metabolism of Bosentan can be decreased when combined with Diltiazem.]
[R03CC08, procaterol, Procaterol may decrease the antihypertensive activities of Bosentan.]
[N02BB04, propyphenazone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Propyphenazone.]
[M01AB14, proglumetacin, The therapeutic efficacy of Bosentan can be decreased when used in combination with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Bosentan can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be increased when combined with Bosentan.]
[N05CD10, quazepam, The metabolism of Quazepam can be increased when combined with Bosentan.]
[C09AA06, quinapril, Bosentan may increase the hypotensive activities of Quinapril.]
[B01AC07, dipyridamole, Bosentan may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Bosentan.]
[N06AA23, quinupramine, Quinupramine may decrease the antihypertensive activities of Bosentan.]
[A03FA02, cisapride, The metabolism of Cisapride can be increased when combined with Bosentan.]
[C09AA05, ramipril, Ramipril may increase the hypotensive activities of Bosentan.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Bosentan.]
[R03CC14, reproterol, Reproterol may decrease the antihypertensive activities of Bosentan.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be increased when used in combination with Bosentan.]
[P03AA04, disulfiram, Bosentan may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[S02AA12, rifamycin SV, The metabolism of Bosentan can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Bosentan can be increased when combined with Rifapentine.]
[N05AX08, risperidone, Risperidone may decrease the antihypertensive activities of Bosentan.]
[N01BB09, ropivacaine, Ropivacaine may increase the hypotensive activities of Bosentan.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Bosentan.]
[A04AD12, aprepitant, The metabolism of Bosentan can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Bosentan.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Bosentan.]
[J05AE07, fosamprenavir, The serum concentration of Bosentan can be increased when it is combined with Fosamprenavir.]
[G04BE08, tadalafil, Bosentan may increase the hypotensive activities of Tadalafil.]
[S01BC05, ketorolac, The therapeutic efficacy of Bosentan can be decreased when used in combination with Ketorolac.]
[C02KX02, ambrisentan, Bosentan may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Bosentan.]
[N02BA06, salsalate, The therapeutic efficacy of Bosentan can be decreased when used in combination with Salsalate.]
[R03AC12, salmeterol, Salmeterol may decrease the antihypertensive activities of Bosentan.]
[C01CA07, dobutamine, Dobutamine may decrease the antihypertensive activities of Bosentan.]
[C01CA04, dopamine, Dopamine may decrease the antihypertensive activities of Bosentan.]
[N06AA16, dothiepin, Dosulepin may decrease the antihypertensive activities of Bosentan.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Bosentan.]
[N06AA12, doxepin, The metabolism of Doxepin can be increased when combined with Bosentan.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Bosentan.]
[N06AB06, sertraline, The metabolism of Sertraline can be increased when combined with Bosentan.]
[N01AB08, sevoflurane, Sevoflurane may decrease the antihypertensive activities of Bosentan.]
[N05AD08, droperidol, Droperidol may decrease the antihypertensive activities of Bosentan.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be decreased when it is combined with Bosentan.]
[C09AA11, spirapril, Bosentan may increase the hypotensive activities of Spirapril.]
[N02CC01, sumatriptan, Sumatriptan may decrease the antihypertensive activities of Bosentan.]
[C07AB13, talinolol, Bosentan may increase the hypotensive activities of Talinolol.]
[M01AC02, tenoxicam, The therapeutic efficacy of Bosentan can be decreased when used in combination with Tenoxicam.]
[G04CA03, terazosin, Bosentan may increase the hypotensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be increased when combined with Bosentan.]
[S01GA02, tetrahydrozoline, Tetryzoline may decrease the antihypertensive activities of Bosentan.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Bosentan.]
[C09AA02, enalapril, Bosentan may increase the hypotensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The therapeutic efficacy of Bosentan can be decreased when used in combination with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Bosentan.]
[N06BA09, atomoxetine, Atomoxetine may decrease the antihypertensive activities of Bosentan.]
[C03CA04, torsemide, The metabolism of Torasemide can be increased when combined with Bosentan.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Bosentan.]
[C09AA10, trandolapril, Trandolapril may increase the hypotensive activities of Bosentan.]
[R03CC11, tulobuterol, Tulobuterol may decrease the antihypertensive activities of Bosentan.]
[C02CA06, urapidil, Urapidil may decrease the antihypertensive activities of Bosentan.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Bosentan.]
[S01FB02, ephedrine, Ephedrine may decrease the antihypertensive activities of Bosentan.]
[C01CX07, xamoterol, Xamoterol may decrease the antihypertensive activities of Bosentan.]
[S01GA03, xylometazoline, Xylometazoline may decrease the antihypertensive activities of Bosentan.]
[C08CA12, mepirodipine, Bosentan may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, The metabolism of Bosentan can be decreased when combined with Epinephrine.]
[C09AA15, zofenopril, Bosentan may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Bosentan.]
[M01AB04, zomepirac, The therapeutic efficacy of Bosentan can be decreased when used in combination with Zomepirac.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be increased when combined with Bosentan.]
[C02AC02, guanfacine, Guanfacine may decrease the antihypertensive activities of Bosentan.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Bosentan.]
[G02AB03, ergonovine, Ergometrine may decrease the antihypertensive activities of Bosentan.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may decrease the antihypertensive activities of Bosentan.]
[N02CA02, ergotamine, The metabolism of Bosentan can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The metabolism of Bosentan can be decreased when combined with Valproic acid.]
[S01AA17, erythromycin, Bosentan may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[A02BC02, pantoprazole, The excretion of Bosentan can be decreased when combined with Pantoprazole.]
[G03CA03, estradiol, The serum concentration of Estradiol can be decreased when it is combined with Bosentan.]
[G03CA57, estrogens, conjugated (USP), The excretion of Bosentan can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Bosentan can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The excretion of Bosentan can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The excretion of Bosentan can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The serum concentration of Fluvastatin can be decreased when it is combined with Bosentan.]
[C01CA15, gepefrine, Gepefrine may decrease the antihypertensive activities of Bosentan.]
[L02AA03, ethinyl estradiol, The serum concentration of Ethinylestradiol can be decreased when it is combined with Bosentan.]
[V03AF05, amifostine, Bosentan may increase the hypotensive activities of Amifostine.]
[M01AC06, meloxicam, The therapeutic efficacy of Bosentan can be decreased when used in combination with Meloxicam.]
[C01CA01, etilefrine, Etilefrine may decrease the antihypertensive activities of Bosentan.]
[N01AX07, etomidate, Etomidate may decrease the antihypertensive activities of Bosentan.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Bosentan.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be increased when combined with Bosentan.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Bosentan.]
[R06AX12, terfenadine, The metabolism of Bosentan can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Bupropion can be increased when combined with Bosentan.]
[N06AB08, fluvoxamine, Bosentan may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[C10AA03, pravastatin, The serum concentration of Pravastatin can be decreased when it is combined with Bosentan.]
[A16AA01, levocarnitine, The excretion of Bosentan can be decreased when combined with Levocarnitine.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Bosentan.]
[C08CA02, felodipine, Bosentan may decrease the excretion rate of Felodipine which could result in a higher serum level.]
[M01AE04, fenoprofen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Fenoprofen.]
[R03CC04, fenoterol, Fenoterol may decrease the antihypertensive activities of Bosentan.]
[N02AB03, fentanyl, Fentanyl may decrease the antihypertensive activities of Bosentan.]
[R03CC02, albuterol, Salbutamol may decrease the antihypertensive activities of Bosentan.]
[L01BB06, clofarabine, Clofarabine may increase the hypotensive activities of Bosentan.]
[C01BC04, flecainide, The metabolism of Bosentan can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Floctafenine.]
[J01CF05, floxacillin, Bosentan may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.]
[J02AC01, fluconazole, The metabolism of Bosentan can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be increased when combined with Bosentan.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be increased when combined with Bosentan.]
[N06AA14, melitracen, Melitracen may decrease the antihypertensive activities of Bosentan.]
[V03AZ01, ethanol, The metabolism of Bosentan can be decreased when combined with Ethanol.]
[L01BC09, floxuridine, The metabolism of Bosentan can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Bosentan can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, The metabolism of Bosentan can be decreased when combined with Fluoxetine.]
[N05AF01, flupenthixol, Flupentixol may decrease the antihypertensive activities of Bosentan.]
[S01BC04, flurbiprofen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Flurbiprofen.]
[N06BX17, adrafinil, Adrafinil may decrease the antihypertensive activities of Bosentan.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Bosentan.]
[J05AE10, darunavir, The serum concentration of Darunavir can be decreased when it is combined with Bosentan.]
[C03CA01, furosemide, Bosentan may increase the hypotensive activities of Furosemide.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be decreased when it is combined with Bosentan.]
[C10AB04, gemfibrozil, The metabolism of Bosentan can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Bosentan.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Bosentan.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be increased when used in combination with Bosentan.]
[J05AG04, etravirine, The metabolism of Etravirine can be increased when combined with Bosentan.]
[G03XA02, gestrinone, The serum concentration of Gestrinone can be decreased when it is combined with Bosentan.]
[N01AH02, alfentanil, Alfentanil may decrease the antihypertensive activities of Bosentan.]
[A10BB01, glyburide, Glyburide may increase the hepatotoxic activities of Bosentan.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Bosentan.]
[A10BB07, glipizide, Bosentan may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the antihypertensive activities of Bosentan.]
[C05AE01, nitroglycerin, Bosentan may increase the hypotensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Bosentan.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be increased when combined with Bosentan.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Bosentan.]
[C07AB09, esmolol, Esmolol may increase the hypotensive activities of Bosentan.]
[B01AA12, fluindione, The metabolism of Fluindione can be increased when combined with Bosentan.]
[C09AA09, fosinopril, Fosinopril may increase the hypotensive activities of Bosentan.]
[S01EX01, guanethidine, Bosentan may increase the hypotensive activities of Guanethidine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Bosentan.]
[N01AB01, halothane, The metabolism of Halothane can be increased when combined with Bosentan.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Bosentan.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin aspart.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Bosentan.]
[C09CA01, losartan, Bosentan may decrease the excretion rate of Losartan which could result in a higher serum level.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Bosentan.]
[A07EC02, mesalamine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Mesalazine.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be increased when combined with Bosentan.]
[R03CC05, hexoprenaline, Hexoprenaline may decrease the antihypertensive activities of Bosentan.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be increased when combined with Bosentan.]
[C08CA10, nilvadipine, The metabolism of Bosentan can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The therapeutic efficacy of Bosentan can be decreased when used in combination with Nimesulide.]
[C09AA04, perindopril, Bosentan may increase the hypotensive activities of Perindopril.]
[C02DB02, hydralazine, Bosentan may increase the hypotensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Hydroflumethiazide.]
[G04BD06, propiverine, Propiverine may decrease the antihypertensive activities of Bosentan.]
[C02AC06, rilmenidine, Rilmenidine may decrease the antihypertensive activities of Bosentan.]
[R02AX02, ibuprofen, The therapeutic efficacy of Bosentan can be decreased when used in combination with Ibuprofen.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be increased when combined with Bosentan.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Bosentan.]
[N01AH03, sufentanil, Sufentanil may decrease the antihypertensive activities of Bosentan.]
[N06AA02, imipramine, Imipramine may decrease the antihypertensive activities of Bosentan.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Bosentan.]
[M03BX02, tizanidine, Tizanidine may increase the hypotensive activities of Bosentan.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Bosentan.]
[S01BC01, indomethacin, Bosentan may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[C02CA02, indoramin, Indoramin may decrease the antihypertensive activities of Bosentan.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Bosentan.]
[R01AA02, cyclopentamine, The risk or severity of adverse effects can be increased when Bosentan is combined with Cyclopentamine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be increased when used in combination with Bosentan.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be increased when combined with Bosentan.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be increased when used in combination with Bosentan.]
[C10AA06, cerivastatin, Bosentan may decrease the excretion rate of Cerivastatin which could result in a higher serum level.]
[C07AA01, alprenolol, Bosentan may increase the hypotensive activities of Alprenolol.]
[N06AA13, iprindole, Iprindole may decrease the antihypertensive activities of Bosentan.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Bosentan.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Bosentan.]
[S01EC03, dorzolamide, Bosentan may increase the hypotensive activities of Dorzolamide.]
[P01AX06, atovaquone, The metabolism of Bosentan can be decreased when combined with Atovaquone.]
[R03CC06, isoetharine, Isoetharine may decrease the antihypertensive activities of Bosentan.]
[C09AA16, imidapril, Bosentan may increase the hypotensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may decrease the antihypertensive activities of Bosentan.]
[J04AC01, isoniazid, The metabolism of Bosentan can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, Isoprenaline may decrease the antihypertensive activities of Bosentan.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be increased when used in combination with Bosentan.]
[C01DA14, isosorbide mononitrate, Bosentan may increase the vasodilatory activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, Isosorbide dinitrate may increase the hypotensive activities of Bosentan.]
[C04AA01, isoxsuprine, Isoxsuprine may decrease the antihypertensive activities of Bosentan.]
[P02CF01, ivermectin, The excretion of Bosentan can be decreased when combined with Ivermectin.]
[L04AC07, tocilizumab, The metabolism of Bosentan can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be increased when combined with Bosentan.]
[C02KD01, ketanserin, Bosentan may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be increased when combined with Bosentan.]
[J02AB02, ketoconazole, The metabolism of Bosentan can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Bosentan can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The metabolism of Bosentan can be decreased when combined with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bosentan.]
[L04AA24, abatacept, The metabolism of Bosentan can be increased when combined with Abatacept.]
[C01CA22, arbutamine, Arbutamine may decrease the antihypertensive activities of Bosentan.]
[N04BC09, rotigotine, Rotigotine may decrease the antihypertensive activities of Bosentan.]
[M01AE11, tiaprofenic acid, The therapeutic efficacy of Bosentan can be decreased when used in combination with Tiaprofenic acid.]
[C07AG01, labetalol, Bosentan may increase the hypotensive activities of Labetalol.]
[C02AA05, deserpidine, Bosentan may increase the hypotensive activities of Deserpidine.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be increased when combined with Bosentan.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the hypotensive activities of Bosentan.]
[A05AA02, ursodiol, Bosentan may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[G03AD01, levonorgestrel, The serum concentration of Levonorgestrel can be decreased when it is combined with Bosentan.]
[N04BA01, levodopa, Levodopa may increase the hypotensive activities of Bosentan.]
[N06BA13, armodafinil, The metabolism of Bosentan can be decreased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be increased when combined with Bosentan.]
[C03DB01, amiloride, Amiloride may increase the hypotensive activities of Bosentan.]
[N02CA07, lisuride, Lisuride may decrease the antihypertensive activities of Bosentan.]
[N06AA07, lofepramine, Lofepramine may decrease the antihypertensive activities of Bosentan.]
[C10AA02, lovastatin, The serum concentration of Lovastatin can be decreased when it is combined with Bosentan.]
[G03DC03, lynestrenol, The serum concentration of Lynestrenol can be decreased when it is combined with Bosentan.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Bosentan.]
[L01EA03, nilotinib, The metabolism of Bosentan can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the hypotensive activities of Bosentan.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Bosentan is combined with Mecamylamine.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Bosentan can be decreased when used in combination with Meclofenamic acid.]
[N02AB02, meperidine, The metabolism of Meperidine can be increased when combined with Bosentan.]
[C01CA11, mephentermine, Mephentermine may decrease the antihypertensive activities of Bosentan.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be increased when combined with Bosentan.]
[N05AX13, paliperidone, Paliperidone may decrease the antihypertensive activities of Bosentan.]
[C01CA09, metaraminol, Metaraminol may decrease the antihypertensive activities of Bosentan.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be increased when used in combination with Bosentan.]
[N07BC02, methadone, The metabolism of Methadone can be increased when combined with Bosentan.]
[N06BA03, methamphetamine, Metamfetamine may decrease the antihypertensive activities of Bosentan.]
[S01EC05, methazolamide, Methazolamide may increase the hypotensive activities of Bosentan.]
[G02CB05, metergoline, Metergoline may decrease the antihypertensive activities of Bosentan.]
[H03BB02, methimazole, The metabolism of Bosentan can be decreased when combined with Methimazole.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Bosentan is combined with Methotrexate.]
[N05AA02, methotrimeprazine, Methotrimeprazine may decrease the antihypertensive activities of Bosentan.]
[C01CA10, methoxamine, Methoxamine may decrease the antihypertensive activities of Bosentan.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be increased when combined with Bosentan.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, Bosentan may increase the hypotensive activities of Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the hypotensive activities of Bosentan.]
[G02AB01, methylergonovine, Methylergometrine may decrease the antihypertensive activities of Bosentan.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Bosentan.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Bosentan.]
[N02CA04, methysergide, The metabolism of Methysergide can be increased when combined with Bosentan.]
[C03BA08, metolazone, Metolazone may increase the hypotensive activities of Bosentan.]
[C07AB02, metoprolol, Metoprolol may increase the hypotensive activities of Bosentan.]
[P01AB01, metronidazole, The metabolism of Bosentan can be decreased when combined with Metronidazole.]
[N06AX03, mianserin, Mianserin may decrease the antihypertensive activities of Bosentan.]
[S02AA13, miconazole, The metabolism of Bosentan can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Aminophenazone.]
[C01CA17, midodrine, Midodrine may decrease the antihypertensive activities of Bosentan.]
[G03XB01, mifepristone, The serum concentration of Mifepristone can be decreased when it is combined with Bosentan.]
[C09CA03, valsartan, The metabolism of Valsartan can be increased when combined with Bosentan.]
[D11AX01, minoxidil, Minoxidil may increase the hypotensive activities of Bosentan.]
[L01XX23, mitotane, The metabolism of Bosentan can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the antihypertensive activities of Bosentan.]
[L03AC01, aldesleukin, Aldesleukin may increase the hypotensive activities of Bosentan.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Bosentan.]
[C01BD01, amiodarone, The metabolism of Bosentan can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be increased when combined with Bosentan.]
[N02AA01, morphine, Morphine may increase the hypotensive activities of Bosentan.]
[L04AB05, certolizumab pegol, The metabolism of Bosentan can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The excretion of Bosentan can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Bosentan.]
[P01BA06, amodiaquine, The metabolism of Bosentan can be decreased when combined with Amodiaquine.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Bosentan is combined with Silodosin.]
[N06AA17, amoxapine, Amoxapine may decrease the antihypertensive activities of Bosentan.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be increased when combined with Bosentan.]
[C07AA12, nadolol, Bosentan may increase the hypotensive activities of Nadolol.]
[N04BC04, ropinirole, Ropinirole may increase the hypotensive activities of Bosentan.]
[V03AB15, naloxone, The metabolism of Bosentan can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Bosentan can be increased when combined with Anakinra.]
[S01GA01, naphazoline, Naphazoline may decrease the antihypertensive activities of Bosentan.]
[N06BA01, amphetamine, Amphetamine may decrease the antihypertensive activities of Bosentan.]
[M02AA12, naproxen, Bosentan may decrease the excretion rate of Naproxen which could result in a higher serum level.]
[A10BG01, troglitazone, The metabolism of Bosentan can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Duloxetine can be increased when combined with Bosentan.]
[N04BX01, tolcapone, Tolcapone may increase the hypotensive activities of Bosentan.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Bosentan.]
[N01AH06, remifentanil, Remifentanil may decrease the antihypertensive activities of Bosentan.]
[A10BX02, repaglinide, Bosentan may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C01CX08, levosimendan, Levosimendan may increase the hypotensive activities of Bosentan.]
[N05AX14, iloperidone, Iloperidone may decrease the antihypertensive activities of Bosentan.]
[J02AA01, amphotericin B, Amphotericin B may increase the hypotensive activities of Bosentan.]
[N06AX23, desvenlafaxine, The metabolism of Bosentan can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, Bosentan may decrease the excretion rate of Telmisartan which could result in a higher serum level.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Bosentan.]
[C08CA04, nicardipine, The metabolism of Bosentan can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may decrease the antihypertensive activities of Bosentan.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be increased when combined with Bosentan.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Bosentan is combined with Nicotine.]
[C08CA05, nifedipine, Bosentan may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The therapeutic efficacy of Bosentan can be decreased when used in combination with Niflumic acid.]
[V03AB22, amyl nitrite, Amyl Nitrite may increase the hypotensive activities of Bosentan.]
[C08CA06, nimodipine, Nimodipine may increase the hypotensive activities of Bosentan.]
[C08CA07, nisoldipine, Nisoldipine may increase the hypotensive activities of Bosentan.]
[C08CA08, nitrendipine, Bosentan may decrease the excretion rate of Nitrendipine which could result in a higher serum level.]
[R07AX01, nitric oxide, Nitric Oxide may increase the hypotensive activities of Bosentan.]
[J01XE01, nitrofurantoin, Bosentan may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may increase the hypotensive activities of Bosentan.]
[C02DD01, nitroprusside, Nitroprusside may increase the hypotensive activities of Bosentan.]
[N01AX13, nitrous oxide, Nitrous oxide may decrease the antihypertensive activities of Bosentan.]
[C01CA03, norepinephrine, Norepinephrine may decrease the antihypertensive activities of Bosentan.]
[G03DC02, norethindrone, The serum concentration of Norethisterone can be decreased when it is combined with Bosentan.]
[G03AC07, norgestrienone, The serum concentration of Norgestrienone can be decreased when it is combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Bosentan.]
[R05DA07, noscapine, The metabolism of Bosentan can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, Nylidrin may decrease the antihypertensive activities of Bosentan.]
[G01AA01, nystatin, The excretion of Bosentan can be decreased when combined with Nystatin.]
[S02AA16, ofloxacin, Bosentan may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[L04AC04, rilonacept, The metabolism of Bosentan can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be increased when combined with Bosentan.]
[N06AA05, opipramol, Opipramol may decrease the antihypertensive activities of Bosentan.]
[R03CB03, metaproterenol, Orciprenaline may decrease the antihypertensive activities of Bosentan.]
[G04CA02, tamsulosin, Tamsulosin may increase the hypotensive activities of Bosentan.]
[C01AC01, ouabain, The excretion of Bosentan can be decreased when combined with Ouabain.]
[A14AA08, oxandrolone, The metabolism of Bosentan can be decreased when combined with Oxandrolone.]
[C07AA02, oxprenolol, Bosentan may increase the hypotensive activities of Oxprenolol.]
[C01DX03, oxyfedrine, Oxyfedrine may decrease the antihypertensive activities of Bosentan.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Bosentan can be decreased when used in combination with Oxymetazoline.]
[S01BC02, oxyphenbutazone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Oxyphenbutazone.]
[V04CH30, 4-aminohippuric acid, The excretion of Bosentan can be decreased when combined with Aminohippuric acid.]
[N05AH05, asenapine, Asenapine may decrease the antihypertensive activities of Bosentan.]
[G03DB06, chlormadinone, The serum concentration of Chlormadinone can be decreased when it is combined with Bosentan.]
[G04BE02, papaverine, Papaverine may increase the hypotensive activities of Bosentan.]
[C02KC01, pargyline, Pargyline may increase the hypotensive activities of Bosentan.]
[C07AA23, penbutolol, Bosentan may increase the hypotensive activities of Penbutolol.]
[S01AA14, penicillin G, Bosentan may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, The metabolism of Bosentan can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Bosentan.]
[N04BC02, pergolide, Pergolide may decrease the antihypertensive activities of Bosentan.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be increased when combined with Bosentan.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Bosentan.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be increased when used in combination with Bosentan.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be increased when combined with Bosentan.]
[C04AX02, phenoxybenzamine, Phenoxybenzamine may decrease the antihypertensive activities of Bosentan.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be increased when combined with Bosentan.]
[A08AA01, phentermine, Phentermine may decrease the antihypertensive activities of Bosentan.]
[V03AB36, phentolamine, Phentolamine may decrease the antihypertensive activities of Bosentan.]
[M02AA01, phenylbutazone, The therapeutic efficacy of Bosentan can be decreased when used in combination with Phenylbutazone.]
[S01GA05, phenylephrine, Phenylephrine may decrease the antihypertensive activities of Bosentan.]
[R01BA01, phenylpropanolamine, Phenylpropanolamine may decrease the antihypertensive activities of Bosentan.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be increased when combined with Bosentan.]
[L04AB06, golimumab, The metabolism of Bosentan can be increased when combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Bosentan.]
[C08CX01, mibefradil, Bosentan may increase the hypotensive activities of Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Bosentan.]
[C07AA03, pindolol, Bosentan may increase the hypotensive activities of Pindolol.]
[C10AA05, atorvastatin, The serum concentration of Atorvastatin can be decreased when it is combined with Bosentan.]
[J05AE01, saquinavir, The serum concentration of Bosentan can be increased when it is combined with Saquinavir.]
[C09CA02, eprosartan, Bosentan may increase the hypotensive activities of Eprosartan.]
[S01BC06, piroxicam, The therapeutic efficacy of Bosentan can be decreased when used in combination with Piroxicam.]
[N02CX01, pizotyline, Pizotifen may decrease the antihypertensive activities of Bosentan.]
[J05AG02, delavirdine, The metabolism of Bosentan can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be increased when combined with Bosentan.]
[A10BG02, rosiglitazone, Bosentan may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[A03AE01, alosetron, The metabolism of Alosetron can be increased when combined with Bosentan.]
[L04AC08, canakinumab, The metabolism of Bosentan can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Bosentan can be increased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Bosentan can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be increased when used in combination with Bosentan.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Bosentan is combined with Insulin lispro.]
[C10AA08, pitavastatin, Bosentan may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C07AB01, practolol, Bosentan may increase the hypotensive activities of Practolol.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Bosentan.]
[P01BA03, primaquine, The metabolism of Bosentan can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Bosentan can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Bosentan can be decreased when combined with Probenecid.]
[S01HA05, procaine, Procaine may increase the hypotensive activities of Bosentan.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Bosentan.]
[C10AB05, fenofibrate, Bosentan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, The serum concentration of Progesterone can be decreased when it is combined with Bosentan.]
[N05AA03, promazine, The metabolism of Promazine can be increased when combined with Bosentan.]
[R06AD02, promethazine, The metabolism of Bosentan can be decreased when combined with Promethazine.]
[C01BC03, propafenone, Propafenone may decrease the antihypertensive activities of Bosentan.]
[N05AC01, periciazine, Periciazine may decrease the antihypertensive activities of Bosentan.]
[N05CM06, propiomazine, Propiomazine may decrease the antihypertensive activities of Bosentan.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Bosentan.]
[N01AX10, propofol, The metabolism of Propofol can be increased when combined with Bosentan.]
[C07AA05, propranolol, Bosentan may increase the hypotensive activities of Propranolol.]
[N02CC04, rizatriptan, Rizatriptan may decrease the antihypertensive activities of Bosentan.]
[B01AC09, epoprostenol, Epoprostenol may increase the hypotensive activities of Bosentan.]
[R03DC03, montelukast, The metabolism of Montelukast can be increased when combined with Bosentan.]
[N06AA11, protriptyline, Protriptyline may decrease the antihypertensive activities of Bosentan.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the antihypertensive activities of Bosentan.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Bosentan.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Bosentan.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be increased when used in combination with Bosentan.]
[C02AA01, rescinnamine, Rescinnamine may decrease the antihypertensive activities of Bosentan.]
[C02AA02, reserpine, The risk or severity of liver damage can be increased when Reserpine is combined with Bosentan.]
[J04AB02, rifampin, The serum concentration of Bosentan can be decreased when it is combined with Rifampicin.]
[R03AC05, rimiterol, Rimiterol may decrease the antihypertensive activities of Bosentan.]
[G02CA01, ritodrine, Ritodrine may decrease the antihypertensive activities of Bosentan.]
[J01FA06, roxithromycin, The excretion of Bosentan can be decreased when combined with Roxithromycin.]
[N02BA05, salicylamide, The therapeutic efficacy of Bosentan can be decreased when used in combination with Salicylamide.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Bosentan can be decreased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Bosentan can be decreased when used in combination with Salicylic acid.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Bosentan.]
[L01FA03, obinutuzumab, Bosentan may increase the hypotensive activities of Obinutuzumab.]
[C07AA07, sotalol, Sotalol may increase the hypotensive activities of Bosentan.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Bosentan.]
[C03DA01, spironolactone, Bosentan may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[J05AE02, indinavir, Strong CYP3A4 inducers - protease inhibitors]
[J05AE04, nelfinavir, Strong CYP3A4 inducers - protease inhibitors]
[J05AE09, tipranavir, Strong CYP3A4 inducers - protease inhibitors]
[J05AE05, amprenavir, Strong CYP3A4 inducers - protease inhibitors]
[J05AE08, atazanavir, Strong CYP3A4 inducers - protease inhibitors]
[J05AE07, fosamprenavir, Strong CYP3A4 inducers - protease inhibitors]
[J05AE10, darunavir, Strong CYP3A4 inducers - protease inhibitors]
[J05AE01, saquinavir, Strong CYP3A4 inducers - protease inhibitors]
[J05AE03, ritonavir, Strong CYP3A4 inducers - protease inhibitors]
